ConsolidatedTable net sales of endovascular products for the quarter ended June 30, 2017 increased 10% on a reported basis (11% on a constant currency basis) compared to the prior year quarter. Consolidated net sales of endovascular products for the six months ended June 30, 2017 increased 9% on a reported basis (10% on a constant currency basis) compared to the prior year period. Net sales in this product line for both the quarter and six months ended June 30, 2017 were favorably impacted by growth in sales of percutaneous transluminal angioplasty (“PTA”) balloon catheters, including drug-coated PTA balloon catheters, stents and biopsy products. Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~June~~September 30, 2017

Commission File Number 1-6926

C. R. BARD, INC.

(Exact name of registrant as specified in its charter)

New Jersey

730 Central Avenue

Murray Hill, New Jersey 07974

22-1454160

(State of incorporation)

(Address of principal

executive offices)

(I.R.S. Employer

Identification No.)

Registrant’s telephone number, including area code: (908) 277-8000

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Class		Outstanding at ~~June~~September 30, 2017
Common Stock - $0.25 par value		72,~~671~~892,~~541~~372

C. R. BARD, INC. AND SUBSIDIARIES

INDEX

		Page
PART I – FINANCIAL INFORMATION
Item 1.	Financial Statements (unaudited)
	Condensed Consolidated Statements of Income for the Quarter and Six Months Ended June 30, 2017 and 2016		3
	Condensed Consolidated Statements of Income for the Quarter and Nine Months Ended September 30, 2017 and 2016		3
	Condensed Consolidated Statements of Comprehensive Income for the Quarter and Six Months Ended June 30, 2017 and 2016		4
	Condensed Consolidated Statements of Comprehensive Income for the Quarter and Nine Months Ended September 30, 2017 and 2016		4
	Condensed Consolidated Balance Sheets – June 30, 2017 and December 31, 2016		5
	Condensed Consolidated Balance Sheets – September 30, 2017 and December 31, 2016		5
	Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2017 and 2016		6
	Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2017 and 2016		6
	Notes to Condensed Consolidated Financial Statements		7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		2120
Item 3.	Quantitative and Qualitative Disclosures About Market Risk		3331
Item 4.	Controls and Procedures		3331
PART II – OTHER INFORMATION
Item 1.	Legal Proceedings		3432
Item 1A.	Risk Factors		3836
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		3836
Item 5.	Other Information		3936
Item 6.	Exhibits		3936
Signatures			4038

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

C. R. BARD, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(dollars in thousands except per share amounts, unaudited)

QuarterEnded June 30,

Six MonthsEnded June 30,

QuarterEnded September 30,

Nine MonthsEnded September 30,

2017

2016

2017

2016

Net sales

~~979~~989,~~700~~800

~~931~~941,~~500~~900

12,~~918~~908,~~500~~300

12,~~805~~746,~~000~~900

Costs and expenses:

Cost of goods sold

~~361~~379,~~300~~200

~~351~~352,~~000~~200

~~715~~1,~~500~~094,700

~~671~~1,~~400~~023,600

Marketing, selling and administrative expense

~~287~~281,~~300~~200

~~278~~272,~~500~~600

~~572~~853,~~700~~900

~~549~~821,~~100~~700

Research and development expense

7471,~~500~~700

7174,~~300~~200

~~144~~216,~~500~~200

~~139~~213,~~600~~800

Interest expense

1514,~~100~~900

1314,~~400~~900

3045,~~200~~100

2439,~~700~~600

Other (income) expense, net

72127,~~700~~400

9115,~~600~~800

85212,~~300~~700

69185,~~600~~400

Total costs and expenses

~~810~~874,~~900~~400

~~723~~829,~~800~~700

12,~~548~~422,~~200~~600

12,~~454~~284,~~400~~100

Income from operations before income taxes

~~168~~115,~~800~~400

~~207~~112,~~700~~200

~~370~~485,~~300~~700

~~350~~462,~~600~~800

Income tax provision

2921,~~100~~300

4815,~~500~~800

5273,~~500~~800

7591,~~200~~000

Net income

~~139~~94,~~700~~100

~~159~~96,~~200~~400

~~317~~411,~~800~~900

~~275~~371,~~400~~800

Basic earnings per share available to common shareholders

1.9028

21.1430

45.3260

35.7000

Diluted earnings per share available to common shareholders

1.8625

21.1127

45.2347

34.6492

The accompanying notes are an integral part of these condensed consolidated financial statements.

C. R. BARD, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(dollars in thousands, unaudited)

QuarterEnded June 30,

Six MonthsEnded June 30,

QuarterEnded September 30,

Nine MonthsEnded September 30,

2017

2016

2017

2016

Net income

~~139~~94,~~700~~100

~~159~~96,~~200~~400

~~317~~411,~~800~~900

~~275~~371,~~400~~800

Other comprehensive income (loss):

Change in derivative instruments designated as cash flow hedges, net of tax

~~800~~(2,000

)

(~~6,300~~400

)

75,400

(15,~~500~~900

)

Foreign currency translation adjustments

2426,~~100~~600

19(12,~~100~~500

)

2855,~~700~~300

208,~~700~~200

Benefit plan adjustments, net of tax

28,~~100~~500

1,700

412,~~300~~800

35,~~400~~100

Other comprehensive income (loss)

2733,~~000~~100

14(11,~~500~~200

)

4073,~~400~~500

8(2,600

)

Comprehensive income

~~166~~127,~~700~~200

~~173~~85,~~700~~200

~~358~~485,~~200~~400

~~284~~369,~~000~~200

The accompanying notes are an integral part of these condensed consolidated financial statements.

C. R. BARD, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(dollars in thousands except share and per share amounts, unaudited)

	June 30,2017			December 31,2016
	September 30,2017			December 31,2016
ASSETS
Current assets
Cash and cash equivalents	$	~~976~~1,~~500~~158,100		$	905,000
Restricted cash		~~153~~142,~~500~~400			201,500
Accounts receivable, less allowances of $4,300 and $7,200, respectively		476,700			477,300
Accounts receivable, less allowances of $4,100 and $7,200, respectively		503,000			477,300
Inventories		~~514~~529,~~800~~300			483,000
Other current assets		~~270~~253,~~400~~300			249,600
Total current assets		2,~~391~~586,~~900~~100			2,316,400
Property, plant and equipment, at cost		~~888~~911,~~700~~000			847,100
Less accumulated depreciation and amortization		~~388~~405,~~900~~400			357,600
Net property, plant and equipment		~~499~~505,~~800~~600			489,500
Goodwill		1,~~266~~271,~~400~~100			1,260,500
Core and developed technologies, net		~~653~~630,~~900~~300			686,400
Other intangible assets, net		~~316~~312,~~900~~100			323,600
Deferred income taxes		60105,~~500~~700			64,400
Other assets		~~164~~161,~~400~~600			165,300
Total assets	$	5,~~353~~572,~~800~~500		$	5,306,100
LIABILITIES AND SHAREHOLDERS’ INVESTMENT
Current liabilities
Short-term borrowings and current maturities of long-term debt	$	~~513~~499,~~600~~800		$	—
Accounts payable		9381,~~200~~000			96,000
Accrued expenses		~~762~~740,~~700~~800			809,500
Accrued compensation and benefits		~~135~~160,~~300~~200			186,100
Income taxes payable		918,~~600~~200			17,300
Total current liabilities		1,~~514~~500,~~400~~000			1,108,900
Long-term debt		1,143,~~300~~500			1,641,700
Other long-term liabilities		~~823~~889,~~200~~500			861,500
Deferred income taxes		1821,~~400~~600			18,900
Commitments and contingencies
Shareholders’ investment:
Preferred stock, $1 par value, authorized 5,000,000 shares; none issued		—			—
Common stock, $0.25 par value, authorized 600,000,000 shares; issued and outstanding 72,671,541 shares at June 30, 2017 and 72,899,251 shares at December 31, 2016		18,200			18,200
Common stock, $0.25 par value, authorized 600,000,000 shares; issued and outstanding 72,892,372 shares at September 30, 2017 and 72,899,251 shares at December 31, 2016		18,200			18,200
Capital in excess of par value		2,~~443~~479,~~500~~700			2,346,800
Accumulated deficit		(~~412~~318,~~100~~000	)		(454,400	)
Accumulated other comprehensive loss		(~~195~~162,~~100~~000	)		(235,500	)
Total shareholders’ investment		12,~~854~~017,~~500~~900			1,675,100
Total liabilities and shareholders’ investment	$	5,~~353~~572,~~800~~500		$	5,306,100

The accompanying notes are an integral part of these condensed consolidated financial statements.

C. R. BARD, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(dollars in thousands, unaudited)

	Six MonthsEnded June 30,
	Nine MonthsEnded September 30,
	2017			2016
Cash flows from operating activities:
Net income	$	~~317~~411,~~800~~900		$	~~275~~371,~~400~~800
Adjustments to reconcile net income to net cash provided by operating activities, net of acquired businesses:
Depreciation and amortization		~~103~~155,~~300~~500			~~107~~160,~~500~~700
Litigation charges, net		75176,~~500~~200			48159,~~900~~200
Restructuring and productivity initiative costs, net of payments		~~3,000~~800			73,~~600~~800
Acquired in-process research and development		1,500			—
Asset impairment		—			1,200
Deferred income taxes		(248,~~300~~800	)		(342,~~400~~800	)
Share-based compensation		5066,~~800~~400			4968,300
Inventory reserves and provision for doubtful accounts		1531,900			1423,~~000~~300
Other items		58,~~600~~900			12,~~900~~100
Changes in assets and liabilities, net of acquired businesses:
Accounts receivable		9(3,~~100~~900	)		(310,~~900~~300	)
Inventories		(4471,~~000~~200	)		(5378,~~800~~700	)
Current liabilities		(~~169~~203,~~500~~900	)		(~~233~~310,~~000~~400	)
Taxes		~~(23~~7,~~200~~000	)		(4019,~~300~~500	)
Other, net		(265,500	)		(155,~~300~~100	)
Net cash provided by operating activities		~~317~~526,~~000~~800			~~156~~344,~~100~~200
Cash flows from investing activities:
Capital expenditures		(4770,~~300~~700	)		(3864,~~400~~600	)
Payments made for purchases of businesses, net of cash acquired		—			(202,800	)
Payments made for intangibles		(1720,~~700~~300	)		(~~400~~600	)
Net cash used in investing activities		(65,000	)		(241,600	)
Other		(8,000	)		—
Net cash used in investing activities		(99,000	)		(268,000	)
Cash flows from financing activities:
Change in short-term borrowings, net		14,000			—
Proceeds from issuance of long-term debt, net		—			495,600
Payment of long-term debt		—			(250,000	)
Proceeds from exercises under share-based compensation plans, net		1734,~~000~~500			1949,~~500~~800
Excess tax benefit relating to share-based compensation plans		—			2435,~~700~~300
Purchases of common stock		(232,300	)		(~~190~~231,~~000~~800	)
Dividends paid		(3857,~~300~~500	)		(3555,~~800~~300	)
Payments of contingent consideration		(~~600~~1,000	)		(1,~~600~~700	)
Net cash (used in) provided by financing activities		(~~240~~256,~~200~~300	)		6241,~~400~~900
Effect of exchange rate changes on cash, cash equivalents, and restricted cash		1122,~~700~~500			~~9,800~~900
Increase (decrease) in cash, cash equivalents, and restricted cash during the period		23,500			(13,300	)
Increase in cash, cash equivalents, and restricted cash during the period		194,000			119,000
Balance at January 1		1,106,500			1,030,900
Balance at June 30	$	1,130,000		$	1,017,600
Balance at September 30	$	1,300,500		$	1,149,900
Supplemental cash flow information
Cash paid for:
Interest	$	2742,~~900~~800		$	2237,~~300~~100
Income taxes		78115,~~000~~600			94118,~~200~~000
Non-cash transactions:
Purchases of businesses and related costs	$	—		$	17,100
Dividends declared, not paid		19,200			19,400

The accompanying notes are an integral part of these condensed consolidated financial statements.

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Basis of Presentation

The ~~accompanying~~ accompanying unaudited condensed consolidated financial statements of C. R. Bard, Inc. and its subsidiaries (the “company” or “Bard”) should be read in conjunction with the audited consolidated financial statements and notes thereto included in Bard’s 2016 Annual Report on Form 10-K. These financial statements have been prepared on a basis that is substantially consistent with the accounting principles applied in the financial statements in Bard’s 2016 Annual Report on Form 10-K. The preparation of these financial statements requires the company to make estimates and judgments that affect reported amounts of assets, liabilities, revenues and expenses and the related disclosure of contingent assets and liabilities at the date of the financial statements. These financial statements include all normal and recurring adjustments necessary for a fair presentation. The accounts of most foreign subsidiaries are consolidated as of and for the quarters ~~ended~~ ~~May~~ended August 31, 2017 and ~~May~~August 31, 2016 and as of November 30, 2016. No events occurred related to these foreign subsidiaries during the months of ~~June~~September 2017, ~~June~~September 2016 or December 2016 that materially affected the ~~financial~~ financial position or results of operations of the company. The results for the interim periods presented are not necessarily indicative of the results expected for the year.

Reclassifications

Certain prior year amounts have been reclassified to conform to current year presentation.

Recently Adopted Accounting Pronouncements

In January 2017, the Financial Accounting Standards Board (“FASB”) issued an accounting standard update that clarifies the definition of a business by providing a more robust framework to evaluate whether transactions should be accounted for as an acquisition of assets or a business. This update is expected to reduce the number of transactions that will be accounted for as an acquisition of a business. The effects of this update will depend on future acquisitions. In 2017, the company adopted this update early.

In November 2016, the FASB issued an accounting standard update that requires the change in the total of cash, cash equivalents, and ~~restricted~~ restricted cash to be shown in the statement of cash flows. As a result, transfers between cash, cash equivalents, and restricted cash will no longer be presented in the statement of cash flows. In 2017, the company adopted this update early on a ~~retrospective~~ retrospective basis. As a result of the adoption, changes in restricted cash of $~~139~~73.41 million are no longer presented as a reduction in cash flows from investing activities in the prior period statement of cash flows. Restricted cash is now included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts.

In October 2016, the FASB issued an accounting standard update that requires the immediate recognition of the income tax effects of intra-entity transfers of assets other than inventory at the time of the transfer. In 2017, the company adopted this update early on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. As a result of the adoption, accumulated deficit was increased by $5.2 million and other current assets and deferred tax liabilities were reduced by $5.4 million and $0.2 million, respectively, as of the beginning of 2017.

In March 2016, the FASB issued an accounting standard update that includes multiple provisions intended to simplify various aspects of the accounting for share-based payments, including the income tax items and the classification of these items on the statement of cash flows. This update will result in the recognition of excess tax benefits to the consolidated statements of income (formerly recorded to capital in excess of par value) upon settlement of share-based compensation awards, which is largely dependent on the exercise/vesting of awards and variables such as the company’s stock price at the time of the exercise/vesting of awards and the exercise price of the underlying awards. This provision of the new guidance, which was required to be applied prospectively, resulted in the recognition of $1012.58 million and $3750.53 million of excess tax benefits in the income tax provision for the quarter and ~~six~~nine months ended ~~June~~September 30, 2017. In addition, cash flows related to these excess tax benefits are now classified as cash flows from operating activities (formerly included as cash flows from financing activities). The company elected to adopt this provision of the new guidance prospectively. Lastly, in the diluted earnings per share available to common shareholders calculation, when applying the treasury stock method for shares that could be repurchased, the assumed proceeds no longer include the amount of excess tax benefits. This did not have a material impact on the company’s diluted earnings per share available to common shareholders calculation.

New Accounting Pronouncements Not Yet Adopted

In March 2017, the FASB issued an accounting standard update that requires that the service cost component of net periodic pension cost be reported in the same income statement line items in which other compensation costs are reported and all other components of net periodic pension cost be reported elsewhere in the income statement. This update will be effective as of the beginning of Bard’s 2018 fiscal year and is not expected to have a material impact on the company’s consolidated financial statements.

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

New Accounting Pronouncements Not Yet Adopted

In February 2016, the FASB issued a new lease accounting standard. The new standard will require, among other items, lessees to recognize most leases on the balance sheet by recording a right-of-use asset and a lease liability. This standard will be effective as of the beginning of Bard’s 2019 fiscal year. Other than this impact to the company’s consolidated balance sheet, the new standard is not expected to have a material impact on the company’s consolidated financial statements.

In May 2014, the FASB issued an accounting standard that provides for a comprehensive model to use in the accounting for revenue arising from contracts with customers. Under this standard, revenue will be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In August 2015, the FASB issued an accounting standard update to defer this standard’s effective date for one year, which will now begin with Bard’s 2018 fiscal year. Under this standard, the company expects to recognize royalty revenue in earlier periods than under its current policy, and to recognize revenue earlier for other contracts that do not meet the new criteria for recognizing revenue over time. In addition, revenue will be recognized in earlier periods where the company maintains risk of loss for products that are in-transit to the customer. The company has made substantial progress in its evaluation of the new standard, and other than these items, this standard is not expected to have a material impact on the company’s consolidated financial statements. The company will continue to assess the new standard, as well as updates to the standard that have been proposed by the FASB. The company intends to adopt the standard under the modified retrospective approach beginning with Bard’s 2018 fiscal year.

2. Becton Dickinson Transaction

On April 23, 2017, Bard entered into an Agreement and Plan of Merger (as amended, the “Merger Agreement”) with Becton, Dickinson and Company (“BD”) and Lambda Corp., a wholly owned subsidiary of BD (“Merger Corp”), pursuant to which Bard will merge with Merger Corp and become a wholly owned subsidiary of BD (the “Merger”). Under the agreement, ~~each~~ each outstanding share of common stock of Bard will be converted into the right to receive $222.93 in cash and 0.5077 of a share of common stock of BD, as may be adjusted pursuant to the terms of the Merger Agreement. Completion of of the Merger is subject to customary closing conditions, including, among others, (1) the approval of the Merger Agreement by a majority of the votes cast by Bard’s shareholders, atwhich aoccurred ~~special~~in ~~meeting~~connection ~~held~~with ~~to vote on~~ the ~~Merger~~special ~~Agreement,~~meeting on ~~among~~August 8, ~~other items~~2017, (2) approval for listing on the New York Stock Exchange of the stock of BD to be issued in the Merger, (3) obtaining antitrust approvals in the United States and certain other jurisdictions, (4) subject to certain exceptions, the accuracy of the representations and warranties of the other party and (5) material compliance by the other party with its obligations under the Merger Agreement. ~~The~~On October 18, 2017, BD received conditional anti-trust approval from the European Commission of the proposed Bard acquisition subject to the divestiture of its core needle biopsy device business. Clearances by the U.S. Federal Trade Commission and certain other regulatory bodies are still pending. The transaction is expected to close in the fourth quarter of 2017. If the Merger Agreement is terminated, Bard may be required to pay BD an amount equal to fifty percent of BD’s out-of-pocket expenses incurred in connection with the Merger Agreement and the Merger and in certain other circumstances, Bard may be required to pay BD a termination fee of $750 million. The foregoing description of the Merger Agreement is qualified in its entirety by reference to the full text of the Merger Agreement attached as Exhibit 2.1 to the Form 8-K filed on April 24, 2017, as amended by Amendment No. 1 attached as Exhibit 2.1 to the Form 8-K filed on July 28, 2017, which isare incorporated by reference herein.

3. Acquisition

On June 22, 2017, the company acquired all of the outstanding shares of PureWick, Inc. (“PureWick”), a privately-held developer and manufacturer of non-invasive female urological drainage products. PureWick received an up-front cash payment at close of $10.0 million and is eligible for future additional milestone payments of up to $20.0 million that are contingent upon specific patent and manufacturing-related milestones being achieved, ~~and~~as well as a sales-based royalty through December 31, 2032. The acquisition of PureWick was accounted for as an acquisition of assets because substantially all the fair value of the gross assets acquired is concentrated in a single identifiable asset. As a result, the company recognized: developed technologies of $14.5 million; deferred tax liabilities of $5.4 million, primarily associated with intangible assets; and other net assets of $0.9 million.

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

4. Earnings per Common Share

Earnings per share (“EPS”) is computed under the two-class method using the following common share information:

	Quarter EndedJune 30,				Six Months EndedJune 30,
	Quarter EndedSeptember 30,				Nine Months EndedSeptember 30,
	2017		2016		2017		2016
(dollars and shares in millions)
EPS Numerator:
Net income	$	~~139~~94.71	$	~~159~~96.24	$	~~317~~411.89	$	~~275~~371.48
Less: Income allocated to participating securities		0.75		0.84		12.72		1.48
Net income available to common shareholders	$	~~139~~93.06	$	~~158~~96.40	$	~~316~~409.17	$	~~274~~370.0
EPS Denominator:
Weighted average common shares outstanding		73.14		74.01		73.12		74.0
Dilutive common share equivalents from share-based compensation plans		1.7		1.2		1.67		1.2
Weighted average common and common equivalent shares outstanding, assuming dilution		7475.81		75.23		74.79		75.2

5. Income Taxes

The effective tax rate for the quarter and ~~six~~nine months ended ~~June~~September 30, 2017 was 1718.25% and 1415.2%, respectively. As discussed in Note 1 of the notes to condensed consolidated financial statements, the company adopted an accounting standard update that resulted in the recognition of excess tax benefits to the income tax provision upon settlement of share-based compensation awards. As a a result, the effective tax rate for the quarter and ~~six~~nine months ended ~~June~~September 30, 2017 reflected a benefit of $1012.58 million and $3750.53 million, respectively. In addition, the effective tax rate for the quarter and ~~six~~nine months ended ~~June~~ September 30, 2017 reflected the discrete tax effects of litigation charges. See Note 8 of the notes to condensed consolidated financial statements.

The effective tax rate for the quarter and ~~six~~nine months ended ~~June~~September 30, 2016 was 2314.41% and 2119.47%, respectively. The effective tax rate for the ~~six~~quarter and nine months ended ~~June~~September 30, 2016 reflected the discrete tax effects of litigation charges related to product liability claims, which were substantially incurred in a high tax jurisdiction. ~~See~~(see Note 8 of the notes to condensed consolidated financial statements) and a benefit of $2.6 million related to the completion of certain U.S. Internal Revenue Service examinations.

At ~~June~~September 30, 2017, the total amount of liability for unrecognized tax benefits related to federal, state and foreign taxes was $2021.53 million (of which $1718.43 million would impact the effective tax rate, if recognized) plus $3.36 million of accrued interest. At December 31, 2016, the liability for unrecognized tax benefits was $21.5 million plus $2.6 million of accrued interest. Depending upon the result of open tax examinations and/or the expiration of applicable statutes of limitation, the company believes it is reasonably possible that the total amount of unrecognized tax benefits may decrease by up to $5.01 million within the next 12 months.

6. Financial Instruments

For further discussion regarding the company’s use of derivative instruments, see Note 1 of the notes to consolidated financial statements in Bard’s 2016 Annual Report on Form 10-K.

Foreign Exchange Derivative Instruments

The company enters into readily marketable forward and option contracts with financial institutions to help reduce its exposure to foreign currency exchange rate fluctuations. These contracts limit volatility because gains and losses associated with foreign currency exchange rate movements are generally offset by movements in the underlying hedged item. The notional value of the company’s forward currency contracts was $~~163~~208.94 million and $243.2 million at ~~June~~September 30, 2017 and December 31, 2016, respectively.

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

The location and fair value of derivative instruments that are designated as hedging instruments recognized in the condensed consolidated balance sheets are as follows:

	Balance SheetLocation		Fair ~~Valueof~~Value of Derivatives
Derivatives Designated as Hedging Instruments			~~June~~September 30,2017		December 31,2016
(dollars in millions)
Forward currency contracts		Other current assets	$	9.94	$	10.9
Forward currency contracts		Other assets		21.6		3.9
			$	1211.50	$	14.8
Forward currency contracts		Accrued expenses	$	—1.1	$	6.2
			$	—	$	6.2
Forward currency contracts		Other long-term liabilities		0.2		—
			$	1.3	$	6.2

The location and amounts of gains and losses on derivative instruments designated as cash flow hedges and the impact on shareholders’ investment are as follows:

	Gain/(Loss)Recognized in OtherComprehensiveIncome (Loss)						Location ofGain/(Loss) Reclassifiedfrom AccumulatedOther Comprehensive Loss intoIncome		Gain/(Loss) Reclassifiedfrom AccumulatedOther Comprehensive Lossinto Income
	Quarter EndedJune 30,								Quarter EndedJune 30,
	Quarter EndedSeptember 30,								Quarter EndedSeptember 30,
	2017			2016					2017			2016
(dollars in millions)
Forward currency contracts	$	(1.70	)	$	(113.05	)		Cost of goods sold	$	~~(0.~~1.4	)	$	(21.32	)
Option currency contracts		—			(10.3	)		Cost of goods sold		—			(0.8	)
Interest rate swap contract		—			~~(0.8~~—	)		Interest expense		(0.56	)		(0.45	)
	$	(1.70	)	$	(133.18	)			$	(0.68	)	$	(32.5	)

	Gain/(Loss)Recognized in OtherComprehensiveIncome (Loss)					Location ofGain/(Loss) Reclassifiedfrom AccumulatedOther Comprehensive Loss intoIncome		Gain/(Loss) Reclassifiedfrom AccumulatedOther Comprehensive Lossinto Income
	Six Months EndedJune 30,							Six Months EndedJune 30,
	Nine Months EndedSeptember 30,							Nine Months EndedSeptember 30,
	2017		2016					2017			2016
(dollars in millions)
Forward currency contracts	$	65.9	$	(1115.83	)		Cost of goods sold	$	(32.40	)	$	(45.79	)
Option currency contracts		—		(3.03	)		Cost of goods sold		(0.4	)		1.0.2
Interest rate swap contract		—		(15.3	)		Interest expense		(1.17	)		(0.49	)
	$	65.9	$	(3033.19	)			$	(4.91	)	$	(46.16	)

Financial Instruments Measured at Fair Value on a Recurring Basis

Fair value is defined as the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that is determined using assumptions that market participants would use in pricing an asset or liability. The fair value guidance establishes a three-level hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs used in measuring fair value. The levels within the hierarchy range from Level 1 having observable inputs to Level 3 having unobservable inputs.

The fair values of the company’s forward currency contracts of $129.57 million and $8.6 million at ~~June~~September 30, 2017 and December 31, 2016, respectively, were measured using significant other observable inputs and valued by reference to similar financial instruments, adjusted for restrictions and other terms specific to each instrument. These financial instruments are categorized as Level 2 under the fair value hierarchy.

The fair value of the liability for contingent consideration related to acquisitions was $14.1 million and $14.9 million at September 30, 2017 and December 31, 2016, respectively. The fair value was measured using significant unobservable inputs and is categorized as Level 3 under the fair value hierarchy.

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

The fair value of the liability for contingent consideration related to acquisitions was $14.5 million and $14.9 million at June 30, 2017 and December 31, 2016, respectively. The fair value was measured using significant unobservable inputs and is categorized as Level 3 under the fair value hierarchy.

Financial Instruments Not Measured at Fair Value

The company maintains a $1 billion five-year committed syndicated bank credit facility that expires in November 2021. The credit facility supports the company’s commercial paper program and can be used for general corporate purposes. The facility includes pricing based on the company’s long-term credit ratings and includes a financial covenant that limits the amount of total debt to total capitalization. At ~~June~~September 30, 2017 the company was in compliance with this covenant. ~~The~~There ~~fair~~were ~~value~~no of commercial paper borrowings outstanding ~~of $14.0 million~~ at ~~June~~September 30, 2017 ~~approximated~~or ~~its carrying value. There were no commercial paper borrowings outstanding at~~ December 31, 2016.

The estimated fair value of long-term debt (including current maturities) was approximately $1,~~712~~707.59 million and $1,688.0 million at ~~June~~ September 30, 2017 and December 31, 2016, respectively. The fair value was estimated using dealer quotes for similarly-rated debt instruments over the remaining contractual term of the company’s obligation and is categorized as Level 2 under the fair value hierarchy.

The fair value of the deferred future payments related to the Medicon, Inc. acquisition of $54.8 million and $52.3 million at ~~June~~September 30, 2017 and December 31, 2016, respectively, approximated the carrying value. At ~~June~~September 30, 2017 and December 31, 2016, future payments of $41.45 million and $39.5 million, respectively, were recorded to other long-term liabilities. These payments will be paid in Japanese Yen and are subject to exchange rate fluctuations. The fair value was estimated by discounting the future payments based upon the timing of such payments and is categorized as Level 2 under the fair value hierarchy.

Concentration Risk

Accounts receivable balances include sales to government-supported healthcare systems outside the United States. The company monitors economic conditions and evaluates accounts receivable in certain countries for potential collection risks. Economic conditions and other factors in certain countries, particularly in Spain, Italy, Greece and Portugal, have resulted in, and may continue to result in, an increase in the average length of time that it takes to collect these accounts receivable and may require the company to re-evaluate the collectability of these receivables in future periods. At ~~June~~September 30, 2017, the company’s accounts receivable, net of allowances, from the national healthcare systems and private sector customers in these four countries was $4244.53 million, of which $2.05 million was greater than 365 days past due.

7. Inventories

Inventories consisted of:

	June 30,2017		December 31,2016
	September 30,2017		December 31,2016
(dollars in millions)
Finished goods	$	~~305~~328.83	$	292.8
Work in process		3929.15		27.0
Raw materials		~~169~~171.95		163.2
	$	~~514~~529.83	$	483.0

8. Contingencies

In the ordinary course of business, the company is subject to various legal proceedings, investigations and claims, including, for example, environmental matters, employment disputes, disputes on agreements and other commercial disputes. In addition, the company operates in an industry susceptible to significant product liability and patent legal claims. The company accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and reasonably estimable. If the estimate of a probable loss is a range and no amount within the range is more likely, the company accrues the minimum amount of the range. Legal costs associated with these matters are expensed as incurred. At any given time, in the ordinary course of business, the company is involved as either a plaintiff or defendant in a number of patent infringement actions. If a third party’s patent infringement claim were to be determined against the company, the company might be required to make significant royalty or other payments or might be subject to an injunction or other limitation on its ability to manufacture or distribute one or more products. If a patent owned by or licensed to the company is found to be invalid or unenforceable, the company might be required to reduce the value of certain intangible assets on the company’s balance sheet and to record a corresponding charge, which could be significant in amount. Many of the company’s legal proceedings and claims could have a material adverse effect on its business, results of operations, financial condition and/or liquidity.

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

8. Contingencies

Product Liability Matters

Hernia Product Claims

As of ~~June~~September 30, 2017, approximately 25 federal and 90185 state lawsuits involving individual claims by approximately ~~115~~ 205 plaintiffs, as well as one putative class action in the United States, are currently pending against the company with respect to its Composix® Kugel® and certain other hernia repair implant products (collectively, the “Hernia Product Claims”). ~~The~~ The company voluntarily recalled certain sizes and lots of the Composix® Kugel® products beginning in December 2005. In June 2007, the Composix® Kugel® lawsuits and, subsequently, other hernia repair product lawsuits, pending in federal courts nationwide were transferred into one Multidistrict Litigation (“MDL”) for coordinated pre-trial proceedings in the United States District Court for the District of Rhode Island. The MDL stopped accepting new cases in the second quarter of 2014 and was terminated in November 2016, at which time the remaining federal lawsuits were remanded to their courts of original jurisdiction for trial. As of ~~June~~September 30, 2017, all but one of the United States putative class actions pending against the ~~company~~ company was dismissed. The remaining putative class action pending against the company has not been certified and seeks: (i) medical monitoring; (ii) compensatory damages; (iii) punitive damages; (iv) a judicial finding of defect ~~and~~ and causation; and/or (v) attorneys’ fees. In April 2014, a settlement was reached with respect to three putative Canadian class actions within amounts previously recorded by the company. As of ~~June~~September 30, 2017, five new putative ~~Canadian~~ Canadian class actions have been filed against the company. Approximately 80170 of the state lawsuits, involving individual claims by approximately 80170 plaintiffs, are pending in the Superior Court of the State of Rhode Island, with the remainder in ~~various~~ various other jurisdictions. The Hernia Product Claims also generally seek damages for personal injury resulting from use of the products.

The company has resolved the majority of its historical Hernia Product Claims, including through agreements or agreements in principle with various plaintiffs’ law firms to settle their respective inventories of cases. Each agreement involving the settlement of a firm’s inventory of claims was subject to certain conditions, including requirements for participation in the proposed settlements by a certain minimum number of plaintiffs. In addition, the company continues to engage in discussions with other plaintiffs’ law firms regarding potential resolution of unsettled Hernia Product Claims, and intends to vigorously defend Hernia Product Claims that do not settle, including through litigation. The company expects additional trials of Hernia Product Claims to take place over the next 12 months. The company cannot give any assurances that the resolution of the Hernia Product Claims that have not settled, including asserted and unasserted claims and the putative class action lawsuit, will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

Women’s Health Product Claims

As of September 30, 2017, product liability lawsuits involving individual claims by approximately 3,285 plaintiffs are currently pending against the company in various federal and state jurisdictions alleging personal injuries associated with the use of certain of the company’s surgical continence products for women, which includes products manufactured by both the company and two subsidiaries of Medtronic plc (as successor in interest to Covidien plc) (“Medtronic”), each a supplier of the company. Medtronic has an obligation to defend and indemnify the company with respect to any product defect liability for products its subsidiaries had manufactured. As described below, in July 2015 the company reached an agreement with Medtronic (which was amended in June 2017) regarding certain aspects of Medtronic’s indemnification obligation. In addition, five putative class actions in the United States and five putative class actions in Canada have been filed against the company, and a limited number of other claims have been filed or asserted in various non-U.S. jurisdictions. The foregoing lawsuits, unfiled or unknown claims, putative class actions and other claims, together with claims that have settled or are the subject of agreements or agreements in principle to settle, are referred to collectively as the “Women’s Health Product Claims”. The Women’s Health Product Claims generally seek damages for personal injury resulting from use of the products. The putative class actions, none of which has been certified, seek: (i) medical monitoring; (ii) compensatory damages; (iii) punitive damages; (iv) a judicial finding of defect and causation; and/or (v) attorneys’ fees. In April 2015, the Ontario Superior Court of Justice dismissed the plaintiffs’ motion for class certification in one Canadian putative class action. In March 2016, the company reached an agreement in principle to resolve all Canadian putative class actions, with the exception of a Quebec class action, within amounts previously recorded by the company, which settlement was finalized in September 2016. In January 2017, the court approved the discontinuance of the proposed Quebec class action.

In October 2010, the Women’s Health Product Claims involving solely Avaulta^® products pending in federal courts nationwide were transferred into an MDL in the United States District Court for the Southern District of West Virginia (the “WV District Court”), the scope of which was later expanded to include lawsuits involving all women’s surgical continence products that are manufactured or distributed by the company. The first trial in a state court was completed in California in July 2012 and resulted in a judgment against the company of approximately $3.6 million. On appeal the decision was affirmed by the appellate court in November 2014. The company filed a petition for review to the California Supreme Court

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

on December 24, 2014, which was denied on February 18, 2015. The judgment in this matter, including interest and costs, was paid on March 20, 2015 within the amounts previously recorded by the company. The first trial in the MDL commenced in July 2013 and resulted in a judgment against the company of approximately $2 million, which was upheld by the Fourth Circuit on January 14, 2016. The company does not believe that any verdicts entered to date are representative of potential outcomes of all Women’s Health Product Claims. On January 16, 2014 and July 31, 2014, the WV District Court ordered that the company prepare 200 and then an additional 300 individual cases, respectively, for trial (the “2014 WHP Pre-Trial Orders”). The 2014 WHP Pre-Trial Orders resulted in significant additional litigation-related defense costs beginning in the second quarter of 2014 and continuing through the second quarter of 2015. In February 2015, the WV District Court appointed a Special Master to assist with settlement resolution. In June 2015, the WV District Court issued an order staying the requirement to prepare a significant portion of the cases covered by the 2014 WHP Pre-Trial Orders. Substantially all of the 500 individual cases that are the subject of the 2014 WHP Pre-Trial Orders have been part of agreements or agreements in principle to settle with various plaintiff law firms. In December 2016, the WV District Court lifted the stay of the 2014 WHP Pre-Trial Orders and remanded five of the unsettled cases to their courts of original jurisdiction for trial. In the first quarter of 2017, an additional 11 cases were remanded for trial for a total of 16 remanded cases. As of September 30, 2017, after accounting for settlements effectuated over the second and third quarters of 2017, there are only three remaining remanded matters, of which two cases have been assigned trial dates in 2018. In response to court orders on January 27, 2017 and March 3, 2017, the company is preparing an additional approximately 125 remaining individual cases for trial (together with the 2014 WHP Pre-Trial Orders, the “WHP Pre-Trial Orders”), which has been reduced from the original order due to settlements and dismissals over the second and third quarters of 2017. The WHP Pre-Trial Orders may result in material additional costs in future periods in defending Women’s Health Product Claims. The WV District Court may also order that the company prepare additional cases for trial, which could result in material additional costs in future periods.

As of ~~June~~September 30, 2017, ~~product~~the ~~liability~~company ~~lawsuits~~reached ~~involving~~agreements ~~individual~~or ~~claims~~agreements byin ~~approximately~~principle ~~4,170~~with ~~plaintiffs are currently pending against the company in~~ various ~~federal~~plaintiffs’ ~~and~~law ~~state~~firms ~~jurisdictions~~to ~~alleging~~settle their ~~personal~~respective ~~injuries~~inventories ~~associated with the use~~ of ~~certain~~cases oftotaling ~~the~~approximately ~~company~~13,050 Women’s ~~surgical~~Health ~~continence~~Product ~~products~~Claims, ~~for~~including ~~women,~~approximately: ~~which~~560 during ~~includes~~2014, ~~products~~6,215 ~~manufactured~~during by2015, ~~both~~4,155 ~~the~~during ~~company~~2016 and ~~two~~ ~~subsidiaries of Medtronic plc (as successor in interest to Covidien plc) (“Medtronic”)~~2,120 ~~each~~during ~~a supplier of the company~~2017. ~~Medtronic~~The ~~has an obligation to defend and indemnify the~~ company ~~with~~believes ~~respect~~that ~~to any product defect liability for~~these ~~products~~Women’s ~~its~~Health ~~subsidiaries~~Product ~~had~~Claims ~~manufactured.~~are Asnot ~~described below, in July 2015~~ the ~~company~~subject ~~reached an agreement with Medtronic (which was amended in June 2017) regarding certain aspects~~ of Medtronic’s indemnification obligation. InThese ~~addition,~~settlement ~~five putative~~agreements ~~class actions in the United States~~ and ~~five~~agreements ~~putative class actions~~ in ~~Canada~~principle ~~have~~include ~~been~~unfiled ~~filed against the company,~~ and apreviously ~~limited~~unknown ~~number of other~~ claims ~~have~~held ~~been~~by ~~filed or asserted in~~ various ~~non-U.S.~~plaintiffs’ ~~jurisdictions.~~law ~~The foregoing lawsuits~~firms, ~~unfiled~~which ~~or unknown claims, putative class actions and other claims, together with claims that~~ have ~~settled~~not orbeen ~~are~~included in the ~~subject~~approximate number of ~~agreements~~lawsuits orset ~~agreements~~forth in ~~principle to settle, are referred to collectively as~~ the ~~“Women’s~~first ~~Health~~paragraph ~~Product Claims”. The Women’s Health Product Claims generally seek damages for personal injury resulting from use~~ of ~~the~~this ~~products~~section. ~~The~~Each ~~putative~~agreement ~~class~~is ~~actions,~~subject ~~none~~to ofcertain ~~which~~conditions, ~~has~~including ~~been~~requirements ~~certified,~~for ~~seek:~~participation ~~(i) medical~~in ~~monitoring; (ii) compensatory~~the ~~damages;~~proposed ~~(iii) punitive~~settlements ~~damages;~~by ~~(iv)~~ a ~~judicial~~certain minimum ~~finding~~number of ~~defect and causation; and/or (v) attorneys’ fees~~plaintiffs. InThe ~~April~~company ~~2015,~~continues ~~the~~to ~~Ontario~~engage ~~Superior~~in ~~Court~~discussions ofwith ~~Justice~~other ~~dismissed the~~ plaintiffs’ ~~motion~~law ~~for class~~firms ~~certification~~regarding inpotential ~~one~~resolution ~~Canadian~~of ~~putative~~unsettled ~~class~~Women’s ~~action.~~Health InProduct ~~March 2016~~Claims, ~~the~~which ~~company~~may ~~reached~~include anadditional ~~agreement~~inventory insettlements. Notwithstanding ~~principle~~these tosettlement ~~resolve all Canadian putative class actions~~efforts, ~~with~~ the ~~exception~~company ofanticipates aadditional ~~Quebec~~trials ~~class~~over ~~action, within amounts previously recorded by~~ the ~~company,~~next ~~which settlement was finalized in September 2016~~12 months. In ~~January 2017~~addition, ~~the~~one ~~court~~or ~~approved~~more ~~the~~possible ~~discontinuance~~consolidated oftrials ~~the~~may ~~proposed~~occur ~~Quebec~~in ~~class~~the ~~action~~future.

In ~~October~~July ~~2010~~2015, ~~the~~as ~~Women’s~~part ~~Health~~of ~~Product~~the ~~Claims~~agreement ~~involving~~noted ~~solely~~above, ~~Avaulta® products~~Medtronic ~~pending~~agreed into ~~federal~~take ~~courts~~responsibility ~~nationwide were transferred into an MDL in the United States District Court~~ for ~~the~~pursuing ~~Southern~~settlement ~~District~~ of ~~West~~certain ~~Virginia (the “WV District Court”), the scope~~ of ~~which was later expanded to include lawsuits~~the ~~involving all women~~Women’s ~~surgical~~Health ~~continence~~Product ~~products~~Claims that ~~are~~relate ~~manufactured~~to orproducts distributed by the company. ~~The~~under ~~first~~supply ~~trial~~agreements inwith aMedtronic ~~state court was completed in California in July 2012~~ and ~~resulted in a judgment against~~ the company ofhas ~~approximately~~ paid Medtronic $~~3.6~~121 million. Ontowards ~~appeal~~these ~~the~~potential ~~decision was affirmed by the appellate court in November 2014~~settlements. ~~The~~In ~~company~~June ~~filed a petition for review to the California Supreme Court on December 24~~2017, ~~2014, which was denied on February 18, 2015. The judgment in this matter, including interest and costs, was paid on March 20, 2015 within~~ the ~~amounts previously recorded by the~~ company. ~~The~~amended ~~first trial in~~ the ~~MDL commenced in July 2013 and resulted in a judgment against the company of approximately $2~~ ~~million,~~agreement ~~which~~with ~~was~~Medtronic ~~upheld by the Fourth Circuit on January 14, 2016. The company does not believe that any verdicts entered~~ to ~~date~~transfer ~~are~~responsibility ~~representative~~for ofsettlement ~~potential outcomes~~ of ~~all~~additional Women’s Health Product Claims. Onto ~~January 16,~~Medtronic ~~2014~~on ~~and July 31,~~terms ~~2014,~~similar ~~the~~to ~~WV District Court ordered that~~ the ~~company~~July prepare 200 and then an additional 300 individual cases, respectively, for trial (the “2014 WHP Pre-Trial Orders”). The 2014 WHP Pre-Trial Orders resulted in significant additional litigation-related defense costs beginning in the second quarter of 2014 and continuing through the second quarter of 2015. ~~In February 2015~~agreement, ~~the~~including WVwith ~~District~~respect ~~Court appointed a Special Master~~ to ~~assist with settlement resolution. In June 2015,~~ the WVobligation ~~District~~to ~~Court~~make ~~issued~~payments ~~an order staying the requirement~~ to ~~prepare~~Medtronic towards athese ~~significant~~potential ~~portion of the cases covered by the 2014 WHP Pre-Trial Orders~~settlements. ~~Substantially~~The ~~all~~company ofalso ~~the~~may, ~~500~~in ~~individual~~its ~~cases~~sole ~~that~~discretion, ~~are~~transfer ~~the~~responsibility ~~subject~~for ofsettlement ~~the 2014 WHP Pre-Trial Orders have been part~~ of ~~agreements~~additional orWomen’s ~~agreements~~Health inProduct ~~principle~~Claims to ~~settle~~Medtronic ~~with~~on ~~various~~similar ~~plaintiff law firms~~terms. InThe ~~December~~agreements ~~2016,~~do ~~the~~not WVresolve ~~District Court lifted~~ the ~~stay~~dispute between of the ~~2014~~company ~~WHP Pre-Trial Orders~~ and ~~remanded~~Medtronic ~~five~~with ofrespect ~~the unsettled cases~~ to ~~their courts~~Women’s ofHealth ~~original~~Product ~~jurisdiction~~Claims ~~for~~that ~~trial.~~do Innot ~~the first quarter of 2017~~settle, anif ~~additional 11 cases were remanded for trial for a total of 16 remanded cases~~any. As ofpart ~~June 30, 2017, after accounting for settlements effectuated over the second quarter~~ of ~~2017, there are only seven remaining remanded matters, of which four cases have been assigned trial dates between~~ the ~~third quarter of 2017 and the third quarter of 2018. In response to court orders on January 27~~agreements, ~~2017~~Medtronic and ~~March 3, 2017,~~ the company isagreed ~~preparing~~to andismiss ~~additional~~without ~~approximately~~prejudice ~~125~~their ~~remaining~~previously ~~individual~~filed ~~cases~~litigation ~~for trial (together~~ with ~~the 2014 WHP Pre-Trial Orders, the “WHP Pre-Trial Orders”), which has been reduced from the original order due to~~respect ~~settlements~~to ~~and dismissals over the second quarter of 2017. The WHP Pre-Trial Orders may result in material additional cost in future periods in defending Women~~Medtronic’s ~~Health~~obligation ~~Product~~to ~~Claims.~~defend ~~The~~and WVindemnify ~~District Court may also order that~~ the company ~~prepare additional cases for trial, which could result in material additional costs in future periods~~.

The approximate number of lawsuits set forth in the first paragraph of this section does not include approximately 555 generic complaints involving women’s health products where the company cannot, based on the allegations in the complaints, determine whether any of those cases involve the company’s women’s health products. In addition, the approximate number of lawsuits set forth in the first paragraph of this section does not include approximately 785 claims that have been threatened against the company but for which complaints have not yet been filed. In addition, the company has limited information regarding the nature and quantity of these and other unfiled or unknown claims. During the course of engaging in settlement discussions with plaintiffs’ law firms, the company has learned, and may in future periods learn, additional information regarding these and other unfiled or unknown claims, or other lawsuits, which could materially impact the company’s estimate of the number of claims or lawsuits against the company. While the company continues to engage in discussions with other plaintiffs’ law firms regarding potential resolution of unsettled Women’s Health Product Claims and intends to vigorously defend the Women’s Health Product Claims that do not settle, including through litigation, it cannot give any assurances that the resolution of these claims will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

As of June 30, 2017, the company reached agreements or agreements in principle with various plaintiffs’ law firms to settle their respective inventories of cases totaling approximately 12,410 Women’s Health Product Claims, including approximately: 560 during 2014, 6,215 during 2015, 4,155 during 2016 and 1,480 during 2017. The company believes that these Women’s Health Product Claims are not the subject of Medtronic’s indemnification obligation. These settlement agreements and agreements in principle include unfiled and previously unknown claims held by various plaintiffs’ law firms, which have not been included in the approximate number of lawsuits set forth in the first paragraph of this section. Each agreement is subject to certain conditions, including requirements for participation in the proposed settlements by a certain minimum number of plaintiffs. The company continues to engage in discussions with other plaintiffs’ law firms regarding potential resolution of unsettled Women’s Health Product Claims, which may include additional inventory settlements. Notwithstanding these settlement efforts, the company anticipates additional trials over the next 12 months. In addition, one or more possible consolidated trials may occur in the future.

In July 2015, as part of the agreement noted above, Medtronic agreed to take responsibility for pursuing settlement of certain of the Women’s Health Product Claims that relate to products distributed by the company under supply agreements with Medtronic and the company has paid Medtronic $121 million towards these potential settlements. In June 2017, the company amended the agreement with Medtronic to transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on terms similar to the July 2015 agreement, including with respect to the obligation to make payments to Medtronic towards these potential settlements. The company also may, in its sole discretion, transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on similar terms. The agreements do not resolve the dispute between the company and Medtronic with respect to Women’s Health Product Claims that do not settle, if any. As part of the agreements, Medtronic and the company agreed to dismiss without prejudice their previously filed litigation with respect to Medtronic’s obligation to defend and indemnify the company.

The approximate number of lawsuits set forth in the first paragraph of this section does not include approximately 555 generic complaints involving women’s health products where the company cannot, based on the allegations in the complaints, determine whether any of those cases involve the company’s women’s health products. In addition, the approximate number of lawsuits set forth in the first paragraph of this section does not include approximately 825 claims that have been threatened against the company but for which complaints have not yet been filed. In addition, the company has limited information regarding the nature and quantity of these and other unfiled or unknown claims. During the course of engaging in settlement discussions with plaintiffs’ law firms, the company has learned, and may in future periods learn, additional information regarding these and other unfiled or unknown claims, or other lawsuits, which could materially impact the company’s estimate of the number of claims or lawsuits against the company. While the company continues to engage in discussions with other plaintiffs’ law firms regarding potential resolution of unsettled Women’s Health Product Claims and intends to vigorously defend the Women’s Health Product Claims that do not settle, including through litigation, it cannot give any assurances that the resolution of these claims will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

Filter Product Claims

As of ~~June~~September 30, 2017, product liability lawsuits involving individual claims by approximately 2,~~245~~765 plaintiffs are currently pending against the company in various federal and state jurisdictions alleging personal injuries associated with the use of the company’s vena cava filter products (all lawsuits, collectively, the “Filter Product Claims”). In August 2015, the Judicial Panel for Multi-District Litigation (“JPML”) ordered the creation of a Multi-District Litigation for all federal Filter Product Claims (the “IVC Filter MDL”) in the District of Arizona. There are approximately 2,~~175~~690 Filter Product Claims that have been, or shortly will be, transferred to the IVC Filter MDL. In September 2017, ~~including~~the ~~one~~Court denied Plaintiffs’ motion seeking class certification of a medical monitoring class ~~action~~. Plaintiffs may appeal this decision. In March 2017, the company filed a motion for summary judgment based upon principles of federal preemption~~, which is scheduled to be fully briefed by the end of the third quarter of 2017~~. The remaining approximately 6570 Filter Product Claims are pending in various state courts. In March 2016, a putative Canadian class action was filed against the company in Quebec. In April 2016 and May 2016, putative Canadian class actions were filed in Ontario and British Columbia, respectively. In November 2016, a putative Canadian class action was filed in Saskatchewan. The approximate number of lawsuits set forth above does not include approximately 2520 claims that have been threatened against the company but for which complaints have not yet been filed. In addition, the company has limited information regarding the nature and quantity of these and other unfiled or unknown claims. The company continues to receive claims and lawsuits and may in future periods learn additional information regarding other unfiled or unknown claims, or other lawsuits, which could materially impact the company’s estimate of the number of claims or lawsuits against the company. The company expects that trials of Filter Product Claims may take place over the next 12 months. While the company intends to vigorously defend Filter Product Claims that do not settle, including through litigation, it cannot give any assurances that the resolution of these claims will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

General

In most product liability litigations (like those described above), plaintiffs allege a wide variety of claims, ranging from allegations of serious injury caused by the products to efforts to obtain compensation notwithstanding the absence of any injury. In many of these cases, the company has not yet received and reviewed complete information regarding the plaintiffs and their medical conditions and, consequently, is unable to fully evaluate the claims. The company expects that it will receive and review additional information regarding any remaining unsettled product liability matters.

The company believes that some settlements and judgments, as well as some legal defense costs, relating to product liability matters are or may be covered in whole or in part under its product liability insurance policies with a limited number of insurance carriers, or, in some circumstances, indemnification obligations to the company from other parties, which if disputed, the company intends to vigorously contest. Amounts recovered under the company’s product liability insurance policies or indemnification arrangements may be less than the stated coverage limits or less than otherwise expected and may not be adequate to cover damages and/or costs relating to claims. In addition, there is no guarantee that insurers or other parties will pay claims or that coverage or indemnity will be otherwise available.

In January 2017, the company reached an agreement to resolve litigation filed in the Southern District of New York by its insurance carriers in connection with Women’s Health Product Claims and Filter Product Claims. The agreement requires the insurance carriers to reimburse the company for certain future costs incurred in connection with Filter Product Claims up to an agreed amount. For certain product liability claims or lawsuits, the company does not maintain or has limited remaining insurance coverage.

The company, its directors, BD and Merger Corp were or have been named as defendants in two putative class actions in the United States District Court of the District of New Jersey, under the captions Barbara Stanford Tanguma v. C. R. Bard, Inc., et al., Case No. 2:17-CV-03977 (filed June 2, 2017) (the “Tanguma action”) and Richard K. Maser v. Timothy M. Ring, et al., Case No. 2:17-CV-04549 (filed June 21, 2017) (the “Maser ~~Action~~action” and, together with the ~~Tanguma~~ Tanguma action, the “lawsuits”). The ~~complaints~~complaint for the ~~lawsuits~~Tanguma ~~allege~~action alleged, and for the Maser action alleges, that the preliminary registration statement on Form S-4 filed by BD on May 23, 2017 contains material misstatements and omits material information in violation of Sections 14(a) and 20(a) of the Exchange Act. The ~~lawsuits~~Tanguma action sought, and the Maser action continues to seek, among other things, equitable relief to enjoin consummation of the Merger and attorneys’ fees and costs. The Tanguma action also ~~seeks~~sought dissemination of a registration statement that is materially true and not misleading and, if the company and BD consummate the Merger, its rescission and/or rescissory damages, and the Maser ~~Action~~action continues ~~also~~to ~~seeks~~seek unspecified damages. On September 25, 2017, the Tanguma action was voluntarily dismissed by the plaintiffs. The company believes that ~~the~~Maser ~~lawsuits~~action ~~are~~is without merit.

~~Other~~14 ~~Legal Matters~~

Since early 2013, the company has received subpoenas or Civil Investigative Demands from a number of State Attorneys General seeking information related to the sales and marketing of certain of the company’s products that are the subject of the Hernia Product Claims and the Women’s Health Product Claims. The company is cooperating with these requests. Although the company has had and continues to have discussions with the State Attorneys General with respect to overall potential resolution of this matter, there can be no assurance that a resolution will be reached or what the terms of any such resolution may be. In the first quarter of 2017, the company recorded a charge to other (income) expense, net, of $7.5 million ($7.5 million after tax). Since it is not feasible to predict the outcome of these proceedings, the company cannot give any assurances that the resolution of these proceedings will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

In November 2015, the Department of Defense Inspector General issued an investigative subpoena to the company. The Department of Health and Human Services is also participating in this investigation. The subpoena seeks documents related to the company’s sales and marketing of certain filter products, drug coated balloon catheters, and peripheral arterial disease detection products. In July 2017, a separate civil investigative demand was served by the Department of Justice seeking documents and information relating to an investigation into possible violations of the False Claims Act in connection with the sales and marketing of FloChec® and QuantaFloTM devices. The company is cooperating with these requests. Since it is not feasible to predict the outcome of these proceedings, the company cannot give any assurances that the resolution of these proceedings will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

InOther ~~June~~Legal ~~2011,~~Matters W. L. Gore & Associates, Inc. (“Gore”) filed suit in the U.S. District Court in Delaware alleging the company had infringed several of Gore’s patents. The trial began March 1, 2017, and was phased such that liability issues would be heard and decided by the jury first, with damages and willfulness to be heard immediately thereafter, if necessary. The liability phase was completed on March 8, 2017 with the jury finding the asserted Gore patent not valid and not infringed. In June 2017, the parties signed a binding term sheet settling the dispute and ending the litigation, and a final agreement was executed in July 2017.

In November 2015, the Department of Defense Inspector General issued an investigative subpoena to the company. The Department of Health and Human Services is also participating in this investigation. The subpoena seeks documents related to the company’s sales and marketing of certain filter products, drug coated balloon catheters, and peripheral arterial disease detection products. In July 2017, a separate civil investigative demand was served by the Department of Justice seeking documents and information relating to an investigation into possible violations of the False Claims Act in connection with the sales and marketing of FloChec^® and QuantaFlo^TM devices. The company is cooperating with these requests. Since it is not feasible to predict the outcome of these proceedings, the company cannot give any assurances that the resolution of these proceedings will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

In June 2011, W. L. Gore & Associates, Inc. (“Gore”) filed suit in the U.S. District Court in Delaware alleging the company had infringed several of Gore’s patents. The trial began March 1, 2017, and was phased such that liability issues would be heard and decided by the jury first, with damages and willfulness to be heard immediately thereafter, if necessary. The liability phase was completed on March 8, 2017 with the jury finding the asserted Gore patent not valid and not infringed. In June 2017, the parties signed a binding term sheet settling the dispute and ending the litigation, and a final agreement was executed in July 2017. The suit was formally dismissed by the Court in September 2017.

The company is subject to numerous federal, state, local and foreign environmental protection laws governing, among other things, the generation, storage, use and transportation of hazardous materials and emissions or discharges into the ground, air or water. The company is or may become a party to proceedings brought under various federal laws including the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA), commonly known as Superfund, the Resource Conservation and Recovery Act, the Clean Water Act, the Clean Air Act and similar state or foreign laws. These proceedings seek to require the owners or operators of contaminated sites, transporters of hazardous materials to the sites and generators of hazardous materials disposed of at the sites to clean up the sites or to reimburse the government for cleanup costs. In most cases, there are other potentially responsible parties that may be liable for remediation costs. In these cases, the government alleges that the defendants are jointly and severally liable for the cleanup costs; however, these proceedings are frequently resolved so that the allocation of cleanup costs among the parties more closely reflects the relative contributions of the parties to the site contamination. The company’s potential liability varies greatly from site to site. For some sites, the potential liability is de minimis and for others the costs of cleanup have not yet been determined. Accruals for estimated losses from environmental remediation obligations generally are recognized no later than completion of the remedial feasibility study and are adjusted as further information develops or circumstances change. Costs of future expenditures for environmental remediation obligations are not discounted to their present value. Recoveries of environmental remediation costs from other parties are recorded as assets when their receipt is deemed probable. The company believes that the proceedings and claims described above will likely be resolved over an extended period of time. While it is not feasible to predict the outcome of these proceedings, based upon the company’s experience, current information and applicable law, the company does not expect these proceedings to have a material adverse effect on its financial condition and/or liquidity. However, one or more of the proceedings could be material to the company’s business and/or results of operations.

Litigation Reserves

The company regularly monitors and evaluates the status of product liability and other legal matters, and may, from time-to-time, engage in settlement and mediation discussions taking into consideration developments in the matters and the risks and uncertainties surrounding litigation. These discussions could result in settlements of one or more of these claims at any time.

In the second quarter of 2015, the company recorded an additional charge related to these matters, net of estimated recoveries to other (income) expense, net, of approximately $337 million ($325 million after tax). The company recorded this charge based on additional information obtained during the quarter, including with respect to the factors noted above. Specifically the company considered the agreement and the agreement in principle by the company to settle approximately 2,880 Women’s Health Product Claims, the involvement of the Special Master in settlement resolution, additional settlements by other manufacturers subject to product liability claims with respect to similar products, and the continued rate of claims being filed (which led the company to increase its estimate of future Women’s Health Product Claims).

In15 the third quarter of 2015, the company recorded an additional charge related to these matters to other (income) expense, net, of approximately $241 million ($228 million after tax). The company recorded this charge based on additional information obtained with respect to the quarter, including with respect to the factors noted above. Specifically, the company considered the agreements and the agreement in principle by the company to settle approximately 3,030 Women’s Health Product Claims, discussions with plaintiffs’ counsel, additional information learned regarding the nature and quantity of unfiled and unknown claims (which led the company to increase its estimate of future Women’s Health Product Claims), a reconciliation of claims in connection with settlements, additional settlements by other manufacturers subject to product liability claims with respect to similar products, the rate of claims being filed, and the creation of the IVC Filter MDL.

In the first quarter of 2016, the company recorded an additional charge related to these matters to other (income) expense, net, of approximately $49 million ($31 million after tax). The company recorded this charge based on additional information obtained with respect to the quarter. Specifically, the company considered, among other factors, additional information learned regarding the nature and quantity of unfiled and filed claims, the increase in advertising by plaintiffs’ counsel with respect to IVC filters and an increase in the rate of claims being filed in Filter Product Claims (which led the company to increase its estimate of future Filter Product Claims).

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Specifically the company considered the agreement and the agreement in principle by the company to settle approximately 2,880 Women’s Health Product Claims, the involvement of the Special Master in settlement resolution, additional settlements by other manufacturers subject to product liability claims with respect to similar products, and the continued rate of claims being filed (which led the company to increase its estimate of future Women’s Health Product Claims).

In the third quarter of 2015, the company recorded an additional charge related to these matters to other (income) expense, net, of approximately $241 million ($228 million after tax). The company recorded this charge based on additional information obtained with respect to the quarter, including with respect to the factors noted above. Specifically, the company considered the agreements and the agreement in principle by the company to settle approximately 3,030 Women’s Health Product Claims, discussions with plaintiffs’ counsel, additional information learned regarding the nature and quantity of unfiled and unknown claims (which led the company to increase its estimate of future Women’s Health Product Claims), a reconciliation of claims in connection with settlements, additional settlements by other manufacturers subject to product liability claims with respect to similar products, the rate of claims being filed, and the creation of the IVC Filter MDL.

In the third quarter of 2016, the company recorded an additional charge related to these matters to other (income) expense, net, of approximately $111 million ($77 million after tax). The company recorded this charge based on additional information obtained with respect to the quarter, including with respect to the factors noted above. Specifically, the company considered, among other factors, additional information learned regarding Product Liability Matters, including regarding the nature and quantity of unfiled and filed claims and the continued rate of claims being filed in certain Product Liability Matters (which led the company to increase its estimate of future claims for certain Product Liability Matters, including Filter Product Claims).

In the fourth quarter of 2016, the company recorded an additional charge related to these matters to other (income) expense, net, of approximately $46 million ($31 million after tax). The company recorded this charge based on additional information obtained with respect to the quarter, including regarding cases settled by certain other manufacturers, public information available from the court, unfiled and filed claims, the status of certain settlement discussions and information regarding plaintiff law firm inventories.

In the second quarter of 2017, the company recorded an additional charge related to these matters to other (income) expense, net, of approximately $52 million ($37 million after tax). The company recorded this charge based on additional information obtained with respect to the quarter. Specifically, the company considered, among other factors, additional information learned regarding Product Liability Matters, including the continued rate of claims being filed in certain Product Liability Matters, including Filter Product Claims.

In the third quarter of 2017, the company recorded an additional charge related to these matters to other (income) expense, net, of approximately $104 million ($80 million after tax). The company recorded this charge based on additional information obtained with respect to the quarter. Specifically, the company considered, among other factors, additional information learned regarding Product Liability Matters, including the nature and quantity of Hernia Product Claims and the continued rate of claims being filed in certain Product Liability Matters, including Filter Product Claims.

These charges recognized the estimated costs for the product liability matters discussed above, including (with respect to such matters) filed and an estimate of unfiled and unknown claims, and costs to administer the settlements related to such matters. These charges exclude any costs associated with certain of the putative class action lawsuits in the United States and Canada.

The company cannot give any assurances that the actual costs incurred with respect to these product liability matters will not exceed the related amounts accrued. With respect to product liability claims that are not resolved through settlement, the company intends to vigorously defend against such claims, including through litigation. The company cannot give any assurances that the resolution of any of its product liability matters, including filed, unfiled and unknown claims and the putative class action lawsuits, will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

~~Accruals~~16 for product liability and other legal matters amounted to $1,145.6 million, of which $584.4 million was recorded to accrued expenses, and $1,201.5 million, of which $605.3 million was recorded to accrued expenses, at June 30, 2017 and December 31, 2016, respectively. The company has made total payments of $829.2 million to qualified settlement funds (“QSFs”), subject to certain settlement conditions, for certain product liability matters since 2011, of which $66.8 million were made to QSFs during the six months ended June 30, 2017. Payments to QSFs are recorded as a component of restricted cash. Total payments of $677.4 million from these QSFs have been made to qualified claimants, of which $114.7 million were made during the six months ended June 30, 2017. In addition, other payments of $82.8 million have been made to qualified claimants, of which $9.5 million were made during the six months ended June 30, 2017.

The company recorded expected recoveries related to product liability matters amounting to $265.4 million, of which $167.3 million was recorded to other current assets, and $267.3 million, of which $156.2 million was recorded to other current assets, at June 30, 2017 and December 31, 2016, respectively. A substantial amount of these expected recoveries at June 30, 2017 and December 31, 2016 relate to the company’s agreements with Medtronic related to certain Women’s Health Product Claims. The terms of the company’s agreements with Medtronic are substantially consistent with the assumptions underlying, and the manner in which, the company has recorded expected recoveries related to the indemnification obligation. The expected recoveries at June 30, 2017 and December 31, 2016 related to the indemnification obligation are not in dispute with respect to claims that Medtronic settles pursuant to the agreements. As described above, the agreements do not resolve the dispute between the company and Medtronic with respect to Women’s Health Product Claims that do not settle, if any, and the company also may, in its sole discretion, transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on similar terms.

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Accruals for product liability and other legal matters amounted to $1,186.0 million, of which $557.3 million was recorded to accrued expenses, and $1,201.5 million, of which $605.3 million was recorded to accrued expenses, at September 30, 2017 and December 31, 2016, respectively. The company has made total payments of $875.3 million to qualified settlement funds (“QSFs”), subject to certain settlement conditions, for certain product liability matters since 2011, of which $112.9 million were made to QSFs during the nine months ended September 30, 2017. Payments to QSFs are recorded as a component of restricted cash. Total payments of $734.5 million from these QSFs have been made to qualified claimants, of which $171.8 million were made during the nine months ended September 30, 2017. In addition, other payments of $84.3 million have been made to qualified claimants, of which $11.0 million were made during the nine months ended September 30, 2017.

The company recorded expected recoveries related to product liability matters amounting to $272.6 million, of which $173.1 million was recorded to other current assets, and $267.3 million, of which $156.2 million was recorded to other current assets, at September 30, 2017 and December 31, 2016, respectively. A substantial amount of these expected recoveries at September 30, 2017 and December 31, 2016 relate to the company’s agreements with Medtronic related to certain Women’s Health Product Claims. The terms of the company’s agreements with Medtronic are substantially consistent with the assumptions underlying, and the manner in which, the company has recorded expected recoveries related to the indemnification obligation. The expected recoveries at September 30, 2017 and December 31, 2016 related to the indemnification obligation are not in dispute with respect to claims that Medtronic settles pursuant to the agreements. As described above, the agreements do not resolve the dispute between the company and Medtronic with respect to Women’s Health Product Claims that do not settle, if any, and the company also may, in its sole discretion, transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on similar terms.

The company is unable to estimate the reasonably possible losses or range of losses, if any, arising from certain existing product liability matters and other legal matters. Under U.S. generally accepted accounting principles, an event is “reasonably possible” if “the chance of the future event or events occurring is more than remote but less than likely” and an event is “remote” if “the chance of the future event or events occurring is slight”. With respect to putative class action lawsuits in the United States and certain of the Canadian lawsuits relating to product liability matters, the company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; (ii) the company has not received and reviewed complete information regarding all or certain of the plaintiffs and their medical conditions; and/or (iii) there are significant factual issues to be resolved. In addition, there is uncertainty as to the likelihood of a class being certified or the ultimate size of the class. With respect to the investigative subpoena issued by the Department of Defense Inspector General and the Department of Health and Human Services and the civil investigative demand served by the Department of Justice, the company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; and/or (ii) there are significant factual and legal issues to be resolved.

9. Share-Based Compensation Plans

The company may grant a variety of share-based payments under the 2012 Long Term Incentive Plan of C. R. Bard, Inc., as amended and restated (the “LTIP”) and the 2005 Directors’ Stock Award Plan of C. R. Bard, Inc., as amended and restated (the “Directors’ Plan”) to certain directors, officers and employees. The total number of remaining shares at ~~June~~September 30, 2017 that may be issued under the LTIP was 2,~~943~~968,~~316~~072 and under the Directors’ Plan was 21,890. Awards under the LTIP may be in the form of stock options, stock appreciation rights, limited stock appreciation rights, restricted stock, unrestricted stock and other stock-based awards. Awards under the Directors’ Plan may be in the form of stock awards, stock options or stock appreciation rights. The company also has two employee stock purchase programs, in which participation has been suspended as a result of the planned Merger.

For the quarters ended ~~June~~September 30, 2017 and 2016, amounts charged against income for share-based payment arrangements were $2315.6 million ~~and~~ and $2319.10 million, respectively. For the ~~six~~nine months ended ~~June~~September 30, 2017 and 2016, amounts charged against income for share-based payment arrangements were $5066.84 million and $4968.3 million, respectively.

In the first quarter of each of 2017 and 2016, the company granted performance restricted stock units to certain officers. These units have requisite service periods of three years and have no dividend rights. The actual payout of these units varies based on the company’s performance over the three-year period based on pre-established targets over the period and a market condition modifier based on total shareholder return (“TSR”) compared to an industry peer group. The actual payout under these awards may exceed an officer’s target payout; however, compensation cost initially recognized assumes that the target payout level will be achieved and may be adjusted for subsequent changes in the expected outcome of the performance-related condition. The fair values of these units are based on the market price of the company’s stock on the date of the grant and use a Monte Carlo simulation model for the TSR component. The fair values of the TSR components of the 2017 and 2016 grants were estimated based on the following assumptions: risk-free interest rate of 1.37% and 0.83%, respectively; dividend yield of 0.47% and 0.52%, respectively; and expected life of 2.89 for both valuations.

As17 of June 30, 2017, there were $118.3 million of unrecognized compensation expenses related to share-based payment arrangements. These costs are expected to be recognized over a weighted-average period of approximately two years. The company has sufficient shares to satisfy expected share-based payment arrangements in 2017.

10. Pension Plans

The company has both tax-qualified and nonqualified, noncontributory defined benefit pension plans, that together cover certain domestic and foreign employees. These plans provide benefits based upon a participant’s compensation and years of service.

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

As of September 30, 2017, there were $103.6 million of unrecognized compensation expenses related to share-based payment arrangements. These costs are expected to be recognized over a weighted-average period of approximately two years. The company has sufficient shares to satisfy expected share-based payment arrangements in 2017.

10. Pension Plans

In the third quarter of 2017, the defined benefit pension plan in the United Kingdom was frozen as to further benefit accruals. This action required a remeasurement of the plans’ assets and obligations, which resulted in a non-cash curtailment gain of $1.7 million. Retirement benefits for future periods for defined benefit plan members who are employed by the company will be provided through an existing defined contribution plan.

The components of net periodic pension cost are as follows:

	Quarter EndedJune 30,						Six Months EndedJune 30,
	Quarter EndedSeptember 30,						Nine Months EndedSeptember 30,
	2017			2016			2017			2016
(dollars in millions)
Service cost, net of employee contributions	$	6.78		$	7.25		$	1320.31		$	1422.50
Interest cost		4.8			4.78			914.64			914.42
Expected return on plan assets		(8.23	)		(8.10	)		(1624.58	)		(1624.2	)
Amortization		3.23			2.6			69.58			57.28
Net periodic pension cost	$	6.5		$	6.4		$	12.9		$	12.9
Curtailment		(1.7	)		—			(1.7	)		—
Net periodic pension cost	$	4.9		$	6.9		$	17.8		$	19.8

11. Shareholders’ Investment

The company repurchased approximately 1.0 million shares of common stock for $232.3 million in the ~~six~~nine months ended ~~June~~September 30, ~~2017~~ 2017 under its previously announced share repurchase authorization.

Other Comprehensive Income (Loss)

The changes in accumulated other comprehensive income (loss) by component are as follows:

	DerivativeInstrumentsDesignated asCash Flow Hedges			Foreign CurrencyTranslationAdjustments			BenefitPlans			Total
(dollars in millions)
Balance at December 31, 2015	$	(8.7	)	$	(94.2	)	$	(105.1	)	$	(208.0	)
Other comprehensive income (loss) before reclassifications		(2831.91	)		208.72			—			(822.29	)
Tax (provision) benefit (a)		8.65			—			—			8.65
Other comprehensive income (loss) before reclassifications, net of taxes		(2022.36	)		208.72			—			0(14.4	)
Reclassifications		46.16	(b)		—			57.28	(c)		914.34
Tax provision (benefit)		0.71			—			(12.87	)		(12.16	)
Reclassifications, net of tax		46.87			—			35.41			811.28
Other comprehensive income (loss)		(15.59	)		208.72			35.41			8(2.6	)
Balance at June 30, 2016	$	(24.2	)	$	(73.5	)	$	(101.7	)	$	(199.4	)
Balance at September 30, 2016	$	(24.6	)	$	(86.0	)	$	(100.0	)	$	(210.6	)
Balance at December 31, 2016	$	(9.9	)	$	(116.0	)	$	(109.6	)	$	(235.5	)
Other comprehensive income (loss) before reclassifications		1.0			28.7			—			29.7
Tax (provision) benefit (a)		1.8			—			—			1.8
Other comprehensive income (loss) before reclassifications, net of taxes		2.8			28.7			—			31.5
Reclassifications		4.9	(b)		—			6.5	(c)		11.4
Tax provision (benefit)		(0.3	)		—			(2.2	)		(2.5	)
Reclassifications, net of tax		4.6			—			4.3			8.9
Other comprehensive income (loss)		7.4			28.7			4.3			40.4
Balance at June 30, 2017	$	(2.5	)	$	(87.3	)	$	(105.3	)	$	(195.1	)

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)


	Derivative Instruments Designated as Cash Flow Hedges			Foreign Currency Translation Adjustments			Benefit Plans			Total
(dollars in millions)
Balance at December 31, 2016	$	(9.9	)	$	(116.0	)	$	(109.6	)	$	(235.5	)
Other comprehensive income (loss) before reclassifications		(0.6	)		55.3			9.4			64.1
Tax (provision) benefit ^(a)		1.9			—			(3.0	)		(1.1	)

Other comprehensive income (loss) before reclassifications, net of taxes		1.3			55.3			6.4			63.0

Reclassifications		4.1	^(b)		—			9.8	^(c)		13.9
Tax provision (benefit)		—			—			(3.4	)		(3.4	)

Reclassifications, net of tax		4.1			—			6.4			10.5

Other comprehensive income (loss)		5.4			55.3			12.8			73.5

Balance at September 30, 2017	$	(4.5	)	$	(60.7	)	$	(96.8	)	$	(162.0	)

(a)	Income taxes are not provided for foreign currency translation adjustment.

(b)	See Note 6 of the notes to condensed consolidated financial statements.

(c)	These components are included in the computation of net periodic pension cost. See Note 10 of the notes to condensed consolidated financial statements.

12. Segment Information

The company’s management considers its business to be a single segment entity – the manufacture and sale of medical devices. The company’s products generally share similar distribution channels and customers. The company designs, develops, manufactures, packages, distributes and sells medical, surgical, diagnostic and patient care devices. The company sells a broad range of products to hospitals, individual healthcare professionals, extended care health facilities and alternate site facilities on a global basis. In general, the company’s products are intended to be used once and then discarded or either temporarily or permanently implanted. The company’s chief operating decision makers evaluate their various global product portfolios on a net sales basis and generally evaluate profitability and associated investment on an enterprise-wide basis due to shared geographic infrastructures.

Net sales based on the location of external customers by geographic region are:

Quarter EndedJune 30,

Six Months EndedJune 30,

Quarter EndedSeptember 30,

Nine Months EndedSeptember 30,

2017

2016

2017

2016

(dollars in millions)

United States

~~660~~665.28

~~633~~646.10

1,~~317~~983.42

1,~~258~~904.5

Europe

114.76

~~115~~108.76

~~217~~332.95

~~220~~328.06

Asia-Pacific(A)

~~144~~149.80

~~127~~131.39

~~271~~420.1

~~225~~357.21

Other(A)

60.04

55.4

~~112~~172.15

~~101~~156.37

~~979~~989.78

~~931~~941.59

12,~~918~~908.53

12,~~805~~746.09

^(A)	Beginning in the fourth quarter of 2016, net sales for Asia-Pacific are separately reported. Prior period amounts have been reclassified to conform to current year presentation.

Total net sales by product group category are:

Quarter EndedJune 30,

Six Months EndedJune 30,

Quarter EndedSeptember 30,

Nine Months EndedSeptember 30,

2017

2016

2017

2016

(dollars in millions)

Vascular

~~277~~289.62

~~255~~258.31

~~534~~823.24

~~494~~752.89

Urology

~~241~~248.34

~~240~~242.01

~~479~~727.04

~~456~~698.78

Oncology

~~266~~270.5

~~252~~258.4

~~522~~792.05

~~494~~752.37

Surgical Specialties

~~169~~157.7

~~159~~158.98

~~334~~492.85

~~311~~470.31

Other

24.60

2324.95

4872.5

4772.94

~~979~~989.78

~~931~~941.59

12,~~918~~908.53

12,~~805~~746.09

2019

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This management’s discussion and analysis provides a review of the results of operations, financial condition and the liquidity and capital resources of C. R. Bard, Inc. and its subsidiaries (the “company” or “Bard”). The following discussion should be read in conjunction with Bard’s 2016 Annual Report on Form 10-K, and the condensed consolidated financial statements and notes thereto included elsewhere in this Form 10-Q. Certain statements contained herein may contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995; see “Risks and Uncertainties; Cautionary Statement Regarding Forward-Looking Information” below.

Overview

The company designs, develops, manufactures, packages, distributes and sells medical, surgical, diagnostic and patient care devices. The company sells a broad range of products to hospitals, individual healthcare professionals, extended care health facilities and alternate site facilities on a global basis. Outside the United States, Europe, Japan and China are the company’s largest markets, while certain emerging markets in Asia, Latin America, and Eastern Europe are the company’s fastest-growing markets. In general, the company’s products are intended to be used once and then discarded or either temporarily or permanently implanted. The company reports sales in four major product group categories: vascular; urology; oncology; and surgical specialties. The company also has a product group category of other products.

The company’s earnings are driven by its ability to continue to generate sales of its products and improve operating efficiency. Bard’s ability to increase sales over time depends upon its success in developing, acquiring and marketing differentiated products that meet the needs of clinicians and their patients. For the ~~six~~nine months ended ~~June~~September 30, 2017, the company’s research and development (“R&D”) expense as a percentage of net sales was 7.54%. The company also makes selective acquisitions of businesses, products and technologies, generally focusing on small-to-medium sized transactions to provide ongoing growth opportunities. In addition, the company may from time-to-time consider acquisitions of larger, established companies. The company may also periodically divest lines of business in which it is not able to reasonably attain or maintain a leadership position in the market or for other strategic reasons.

Recent Developments

Becton Dickinson Transaction

On April 23, 2017, Bard entered into an Agreement and Plan of Merger (as amended, the “Merger Agreement”) with Becton, Dickinson and Company (“BD”) and Lambda Corp., a wholly owned subsidiary of BD (“Merger Corp”), pursuant to which Bard will merge with Merger Corp and become a wholly owned subsidiary of BD (the “Merger”). Under the agreement, each outstanding share of common stock of Bard will be converted into the right to receive $222.93 in cash and 0.5077 of a share of common stock of BD, as may be adjusted pursuant to the terms of the Merger Agreement. Completion of the Merger is subject to customary closing conditions, including, among others, (1) the approval of the Merger Agreement by a majority of the votes cast by Bard’s shareholders, atwhich aoccurred ~~special~~in ~~meeting~~connection ~~held~~with tothe ~~vote~~special meeting on ~~the Merger Agreement~~August 8, ~~among other items~~2017, (2) approval for listing on the New York Stock Exchange of the stock of BD to be issued in the Merger, (3) obtaining antitrust approvals in the United States and certain other jurisdictions, (4) subject to certain exceptions, the accuracy of the representations and warranties of the other party and (5) material compliance by the other party with its obligations under the Merger Agreement. On October 18, 2017, BD received conditional anti-trust approval from the European Commission of the proposed Bard acquisition subject to the divestiture of its core needle biopsy device business. Clearances by the U.S. Federal Trade Commission and certain other regulatory bodies are still pending. The transaction is expected to close in the fourth quarter of 2017. If the Merger Agreement is terminated, Bard may be required to pay BD an amount equal to fifty percent of BD’s out-of-pocket expenses incurred in connection with the Merger Agreement and the Merger and in certain other circumstances, Bard may be required to pay BD a termination fee of $750 million. The foregoing description of the Merger Agreement is qualified in its entirety by reference to the full text of the Merger Agreement attached as Exhibit 2.1 to the Form 8-K filed on April 24, 2017, as amended by Amendment No. 1 attached as Exhibit 2.1 to the Form 8-K filed on July 28, 2017, which isare incorporated by reference herein.

Legal Developments

In the third quarter of 2017, the company recorded an additional charge related to product liability matters to other (income) expense, net, of approximately $104 million ($80 million after tax).

In the second quarter of 2017, the company recorded an additional charge related to product liability matters to other (income) expense, net, of approximately $52 million ($37 million after tax).

For more information on legal matters, see Note 8 of the notes to condensed consolidated financial statements.

~~Acquisition~~20

Hurricane

On September 20, 2017, Hurricane Maria made landfall and damaged the company’s manufacturing operations in Puerto Rico. The company has accounted for all of its employees in Puerto Rico and all are safe. The company’s facilities on the island sustained minor damage that has since been repaired. Manufacturing has recently resumed and is operating normally, but under generator power at this time. The company expects the disruption in manufacturing to have a negative impact on fourth quarter revenue and operations, but expects this impact to be temporary in nature and to be resolved by the end of 2017.

Acquisition

Results of Operations

Net Sales

Bard’s consolidated net sales for the quarter ended ~~June~~September 30, 2017 increased 5% on both a reported basis ~~(6%~~and ~~on a~~ constant currency basis) compared to the same period in the prior year. Bard’s consolidated net sales for the ~~six~~nine months ended ~~June~~September 30, 2017 ~~increased~~ increased 6% on a reported basis (7% on a constant currency basis) compared to the same period in the prior year. Net sales “on a constant currency basis” is a non-GAAP measure and should not be viewed as a replacement of GAAP results. See “Management’s Use of Non-GAAP Measures” below. Price changes had the effect of decreasing consolidated net sales for ~~both~~ the quarter ~~and~~ended ~~six~~September 30, 2017 by approximately 20 basis points as compared to the same period in the prior year. Price changes had the effect of decreasing consolidated net sales for the nine months ended ~~June~~September 30, 2017 by approximately 30 basis points as compared to the same ~~periods~~ period in the prior year. Exchange rate fluctuations had a nominal effect on consolidated net sales for the quarter ended September 30, 2017, as compared to the same period in the prior year. Exchange fluctuations had the effect of decreasing consolidated net sales for ~~both~~ the ~~quarter~~nine ~~and six~~ months ended ~~June~~ September 30, 2017 by approximately one percentage point, as compared to the same ~~periods~~period in the prior year. The primary exchange rate movements that impacted net sales were the movement of the British Pound, Japanese Yen, Chinese Renminbi and the Euro compared to the U.S. dollar. The impact of exchange rate fluctuations on net sales is not indicative of the impact on net earnings due to the offsetting impact of exchange rate movements on operating costs and expenses, costs incurred in other currencies and the company’s hedging activities. For the quarter ended September 30, 2017, the company experienced two issues that combined to reduce reported third quarter revenue by approximately 150 basis points. About half of this impact was related to reduced sales as a result of the hurricane activity during the quarter. The other half of the impact was related to a supply issue with the company’s surgical sealant line.

Bard’s United States net sales of $~~660~~665.28 million for the quarter ended ~~June~~September 30, 2017 increased 43% compared to $~~633~~646.10 million in ~~the~~ the prior year quarter. International net sales of $~~319~~324.50 million for the quarter ended ~~June~~September 30, 2017 increased 79% on a reported basis (1110% on a constant currency basis) compared to $~~298~~295.49 million in the prior year quarter. Bard’s ~~United~~ United States net sales of $1,~~317~~983.42 million for the ~~six~~nine months ended ~~June~~September 30, 2017 increased 54% compared to $1,~~258~~904.5 million in the prior year period. International net sales of $~~601~~925.1 million for the ~~six~~nine months ended ~~June~~September 30, 2017 increased 10% on a reported basis (1412% on a constant currency basis) compared to $~~546~~842.54 million in the prior year period.

A summary of net sales by product group category is as follows:

Product Group Summary of Net Sales

	Quarter Ended June 30,										Six Months Ended June 30,
	Quarter Ended September 30,										Nine Months Ended September 30,
	2017		2016		Change			ConstantCurrency			2017		2016		Change			ConstantCurrency
(dollars in millions)
Vascular	$	~~277~~289.62	$	~~255~~258.31		912	%		1012	%	$	~~534~~823.24	$	~~494~~752.89		89	%		910	%
Urology		~~241~~248.34		~~240~~242.01		13	%		23	%		~~479~~727.04		~~456~~698.78		54	%		65	%
Oncology		~~266~~270.5		~~252~~258.4		65	%		75	%		~~522~~792.05		~~494~~752.37		65	%		6	%
Surgical Specialties		~~169~~157.7		~~159~~158.98		6(1	)%		7(1	)%		~~334~~492.85		~~311~~470.31		85	%		85	%
Other		24.60		2324.95		3(2	)%		6(1	)%		4872.5		4772.94		1—	%		42	%
Total net sales	$	~~979~~989.78	$	~~931~~941.59		5	%		65	%	$	12,~~918~~908.53	$	12,~~805~~746.09		6	%		7	%

~~Vascular~~21 Products - Bard markets a wide range of products for the peripheral vascular market, including endovascular products and vascular graft products. Also included within vascular products are royalty payments from W. L. Gore & Associates, Inc. (“Gore”), which will end in 2019. Consolidated net sales of vascular products for the quarter ended June 30, 2017 increased 9% on a reported basis (10% on a constant currency basis) compared to the prior year quarter. Consolidated net sales of vascular products for the six months ended June 30, 2017 increased 8% on a reported basis (9% on a constant currency basis) compared to the prior year period. These increases were primarily due to growth in sales of endovascular products. United States net sales of vascular products for the quarter ended June 30, 2017 increased 8% compared to the prior year quarter. International net sales of vascular products for the quarter ended June 30, 2017 increased 11% on a reported basis (15% on a constant currency basis) compared to the prior year quarter. United States net sales of vascular products for the six months ended June 30, 2017 increased 6% compared to the prior year period. International net sales of vascular products for the six months ended June 30, 2017 increased 11% on a reported basis (14% on a constant currency basis) compared to the prior year period.

Vascular Products - Bard markets a wide range of products for the peripheral vascular market, including endovascular products and vascular graft products. Also included within vascular products are royalty payments from W. L. Gore & Associates, Inc. (“Gore”), which will end in 2019. Consolidated net sales of vascular products for the quarter ended September 30, 2017 increased 12% on both a reported basis and constant currency basis compared to the prior year quarter. Consolidated net sales of vascular ~~graft~~products for the nine months ended September 30, 2017 increased 9% on a reported basis (10% on a constant currency basis) compared to the prior year period. These increases were primarily due to growth in sales of endovascular products. United States net sales of vascular products for the quarter ended ~~June~~September 30, 2017 ~~decreased~~increased 611% compared to the prior year quarter. International net sales of vascular products for the quarter ended September 30, 2017 increased 14% on a reported basis (413% on a constant currency basis) compared to the prior year quarter. ~~Consolidated~~United States net sales of vascular ~~graft~~ products for the ~~six~~nine months ended September 30, 2017 increased 8% compared to the prior year period. International net sales of vascular products for the nine months ended ~~June~~September 30, 2017 ~~decreased~~increased 512% on a reported basis (314% on a constant currency basis) compared to the prior year period.

Consolidated net sales of endovascular products for the quarter ended September 30, 2017 increased 13% on both a reported basis and constant currency basis compared to the prior year quarter. Consolidated net sales of endovascular products for the nine months ended September 30, 2017 increased 11% on both a reported basis and constant currency basis compared to the prior year period. Net sales in this product line for both the quarter and nine months ended September 30, 2017 were favorably impacted by growth in sales of percutaneous transluminal angioplasty (“PTA”) balloon catheters, including drug-coated PTA balloon catheters, stents and biopsy products.

Consolidated net sales of vascular graft products for the quarter ended September 30, 2017 decreased 5% on both a reported basis and constant currency basis compared to the prior year quarter. Consolidated net sales of vascular graft products for the nine months ended September 30, 2017 decreased 5% on a reported basis (4% on a constant currency basis) compared to the prior year period.

Urology Products - Bard markets a wide range of products for the urology market, including basic urology drainage products, fecal and urinary continence products and urological specialty products. Bard also markets StatLock^® catheter stabilization products, which are used to secure many types of catheters sold by Bard and other companies, as well as Targeted Temperature Management™ products, which are used for therapeutic hypothermia. Consolidated net sales of urology products for the quarter ended September 30, 2017 increased 3% on both a reported basis and constant currency basis compared to the prior year quarter. Consolidated net sales of urology products for the nine months ended September 30, 2017 increased 4% on a reported basis (5% on a constant currency basis) compared to the prior year period. This increase includes 2 percentage points of growth on both a reported basis and constant currency basis from the impact of selling inventory acquired in the Medicon, Inc. (“Medicon”) acquisition during the nine months ended September 30, 2016, which was recorded as sales into the joint venture prior to the acquisition. Net sales for the quarter and nine months ended September 30, 2017 were also favorably impacted by growth in sales of basic drainage products, urological specialty products and Targeted Temperature Management™ products. These increases were partially offset by a decline in sales of continence products. United States net sales of urology products for the quarter ended September 30, 2017 increased 4% compared to the prior year quarter. International net sales of urology products for the quarter ended September 30, 2017 were flat on a reported basis (increased 2% on a constant currency basis) compared to the prior year quarter. United States net sales of urology products for the nine months ended September 30, 2017 increased 4% compared to the prior year period. International net sales of urology products for the nine months ended September 30, 2017 increased 5% on a reported basis (9% on a constant currency basis) compared to the prior year period.

Consolidated net sales of basic drainage products for the quarter ended September 30, 2017 increased 2% on a reported basis (3% on a constant currency basis) compared to the prior year quarter. Consolidated net sales of basic drainage products for the nine months ended September 30, 2017 increased 6% on a reported basis (7% on a constant currency basis) compared to the prior year period. The increase for the nine months ended September 30, 2017 was primarily due to sales as a result of the Medicon acquisition.

Consolidated net sales of urological specialty products for the quarter ended September 30, 2017 increased 4% on a reported basis (5% on a constant currency basis) compared to the prior year quarter. Consolidated net sales of urological specialty products for the nine months ended September 30, 2017 increased 6% on a reported basis (7% on a constant currency basis) compared to the prior year period.

Consolidated net sales of continence products for the quarter ended September 30, 2017 decreased 1% on a reported basis (flat on a constant currency basis) compared to the prior year quarter. Consolidated net sales of continence products for the nine months ended September 30, 2017 decreased 5% on a reported basis (3% on a constant currency basis) compared to the prior year period. These decreases were primarily due to a decline in sales surgical continence products, a trend that is expected to continue. For the quarter ended September 30, 2017, these declines were partially offset by an increase in sales of other continence products.

~~Urology~~Consolidated ~~Products~~net -sales ~~Bard markets a wide range~~ of ~~products for~~ the ~~urology market, including basic urology drainage products, fecal and urinary continence products and urological specialty products. Bard also markets~~ StatLock® catheter stabilization ~~products,~~product ~~which~~line ~~are used to secure many types of catheters sold by Bard and other companies, as well as Targeted Temperature Management™ products, which are used~~ for ~~therapeutic hypothermia. Consolidated net sales of urology products for~~ the quarter ended ~~June~~September 30, 2017 increased 1% on both a reported basis ~~(2%~~and ~~on a~~ constant currency basis) compared to the prior year quarter. Consolidated net sales of ~~urology products for~~ the six months ended June 30, 2017 increased 5% on a reported basis (6% on a constant currency basis) compared to the prior year period. This increase includes 3 percentage points of growth on both a reported basis and constant currency basis from the impact of selling inventory acquired in the Medicon, Inc. (“Medicon”) acquisition during the six months ended June 30, 2016, which was recorded as sales into the joint venture prior to the acquisition. Net sales for the quarter and six months ended June 30, 2017 were also favorably impacted by growth in sales of basic drainage products, urological specialty products and StatLock® catheter stabilization ~~products.~~product ~~These~~line ~~increases were partially offset by a decline in sales of continence products. United States net sales of urology products~~ for the ~~quarter~~nine ~~ended~~months ~~June 30, 2017 increased 2% compared to the prior year quarter. International net sales of urology products for the quarter~~ ended ~~June~~September 30, 2017 ~~decreased 2% on a reported basis (~~increased 23% on aboth ~~constant currency basis) compared to the prior year quarter. International net sales for the quarter ended June 30, 2017 reflected~~ a decline in sales of continence products. United States net sales of urology products for the six months ended June 30, 2017 increased 4% compared to the prior year period. International net sales of urology products for the six months ended June 30, 2017 increased 8% on a reported basis ~~(12%~~and ~~on a~~ constant currency basis) compared to the prior year period.

Oncology Products - Bard’s oncology business includes specialty vascular access products and enteral feeding devices. Specialty vascular access products include peripherally inserted central catheters (“PICCs”) used for intermediate to long-term central venous access, specialty access ports and accessories (“Ports”) used most commonly for chemotherapy, dialysis access catheters and vascular access ultrasound devices, which help facilitate the placement of PICCs. Consolidated net sales of ~~basic~~oncology ~~drainage~~ products for the quarter ended ~~June~~September 30, 2017 increased 15% on both a reported basis ~~(2% on a~~ and constant currency basis) compared to the prior year quarter. Consolidated net sales of ~~basic~~oncology ~~drainage~~ products for the ~~six~~nine months ended ~~June~~September 30, 2017 increased 85% on a reported basis (96% on a constant currency basis) compared to the prior year period. These increases were primarily due to growth in sales of PICCs, Ports and dialysis access catheters. United States net sales of oncology products for the quarter ended September 30, 2017 were flat compared to the prior year ~~period~~quarter. International ~~The~~net ~~increase~~sales of oncology products for the ~~six~~quarter ended September 30, 2017 increased 14% on both a reported basis and constant currency basis compared to the prior year quarter. United States net sales of oncology products for the nine months ended ~~June~~September 30, 2017 ~~was~~increased ~~primarily~~3% ~~due~~compared to the prior year period. International net sales asof oncology products for the nine months ended September 30, 2017 increased 11% on a ~~result~~reported ofbasis (13% on a constant currency basis) compared to the ~~Medicon~~prior ~~acquisition~~year period.

Consolidated net sales of ~~urological~~PICCs ~~specialty products~~ for the quarter ended ~~June~~September 30, 2017 increased 7% on both a reported basis ~~(9%~~and ~~on a~~ constant currency basis) compared to the prior year quarter. Consolidated net sales of ~~urological~~PICCs ~~specialty products~~ for the ~~six~~nine months ended ~~June~~September 30, 2017 increased 67% on a reported basis (78% on a constant currency basis) compared to the prior year period.

Consolidated net sales of ~~continence~~Ports ~~products~~ for the quarter ended ~~June~~September 30, 2017 ~~decreased~~increased 92% on both a reported basis ~~(7%~~ onand a constant currency basis) compared to the prior year quarter. Consolidated net sales of ~~continence~~Ports ~~products~~ for the ~~six~~nine months ended ~~June~~September 30, 2017 ~~decreased~~increased 84% on a reported basis (5% on a constant currency basis) compared to the prior year period. ~~These decreases were due to declines in sales of other continence products and surgical continence products, a trend that is expected to continue.~~

Consolidated net sales of dialysis access catheters for the ~~StatLock®~~quarter ~~catheter~~ended ~~stabilization~~September 30, ~~product~~2017 ~~line~~increased ~~for~~11% ~~the~~on both a reported basis and constant currency basis compared to the prior year quarter. Consolidated net sales of dialysis access catheters for the nine months ended ~~June~~September 30, 2017 increased 28% on a reported basis (39% on a constant currency basis) compared to the prior year ~~quarter~~period. Consolidated net sales of vascular access ultrasound devices for the ~~StatLock®~~quarter ~~catheter~~ended September 30, 2017 increased 2% on both a reported basis and constant currency basis compared to the prior year quarter. Consolidated net ~~stabilization~~sales ~~product~~of ~~line~~vascular access ultrasound devices for the ~~six~~nine months ended ~~June~~September 30, 2017 ~~increased~~decreased 41% on ~~both~~ a reported basis ~~and~~(flat on a constant currency basis) compared to the prior year period.

~~Oncology~~Surgical Specialty Products - ~~Bard’s~~Surgical ~~oncology~~specialty ~~business~~products ~~includes~~include ~~specialty~~soft ~~vascular~~tissue ~~access~~repair products, ~~and~~performance ~~enteral~~irrigation ~~feeding~~ devices. ~~Specialty~~and ~~vascular~~biosurgery ~~access~~ products, ~~include~~including ~~peripherally~~hemostats ~~inserted~~and ~~central~~sealants. ~~catheters~~Consolidated ~~(“PICCs”)~~net ~~used~~sales ~~for~~of ~~intermediate~~surgical tospecialty ~~long-term~~products ~~central~~for ~~venous~~the ~~access~~quarter ended September 30, ~~specialty~~2017 ~~access~~decreased ~~ports~~1% on both a reported basis and ~~accessories~~constant ~~(“Ports”)~~currency ~~used~~basis ~~most~~compared ~~commonly~~to ~~for~~the ~~chemotherapy,~~prior year ~~dialysis~~quarter. ~~access~~The ~~catheters~~decrease ~~and~~in ~~vascular~~net ~~access~~sales ~~ultrasound~~for ~~devices,~~the ~~which~~quarter ~~help~~ended ~~facilitate~~September 30, ~~the~~2017 ~~placement~~was ofprimarily ~~PICCs.~~due ~~Consolidated~~to ~~net~~a decline in sales of ~~oncology~~biosurgery products, ~~for~~due to the ~~quarter~~supply ~~ended~~issue ~~June 30~~noted below, ~~2017~~and ~~increased~~was 6%partially onoffset aby ~~reported~~an ~~basis~~increase ~~(7%~~in onsales aof ~~constant~~synthetic ~~currency~~hernia ~~basis)~~repair ~~compared~~products. In addition, the hurricanes during the quarter contributed to the ~~prior~~decline ~~year~~in net sales for the quarter ended September 30, 2017. Consolidated net sales of ~~oncology~~surgical specialty products for the ~~six~~nine months ended ~~June~~ September 30, 2017 increased 65% on both a reported basis and constant currency basis compared to the prior year period. ~~These increases~~The ~~were~~increase in net sales for the nine months ended September 30, 2017 was primarily due to growth in sales of synthetic ~~PICCs~~hernia repair products and ~~Ports~~was partially offset by declines in sales of natural hernia repair products and biosurgery products. United States net sales of ~~oncology~~surgical specialty products for the quarter ended ~~June~~September 30, 2017 ~~increased~~ decreased 4% compared to the prior year quarter. International net sales of ~~oncology~~surgical specialty products for the quarter ended ~~June~~September 30, 2017 increased 10% on both a reported basis ~~(13%~~and ~~on a~~ constant currency basis) compared to the prior year quarter. United States net sales of ~~oncology~~surgical specialty products for the ~~six~~nine months ended ~~June~~September 30, 2017 increased 42% compared to the prior year period. International net sales of ~~oncology~~surgical specialty products for the ~~six~~nine months ended ~~June~~ September 30, 2017 increased 915% on a reported basis (1217% on a constant currency basis) compared to the prior year period. The increase in international net sales for the quarter and nine months ended September 30, 2017 were primarily due to growth in sales of synthetic hernia repair products, biosurgery products and hernia fixation products, and was partially offset by the supply issue noted below.

The soft tissue repair product line includes synthetic and natural tissue hernia repair implants, natural tissue breast reconstruction implants and hernia fixation products. Consolidated net sales of ~~PICCs~~soft tissue repair products for the quarter ended ~~June~~September 30, 2017 increased 63% on both a reported basis ~~(8%~~and ~~on a~~ constant currency basis) compared to the prior year quarter. Consolidated net sales of ~~PICCs~~soft tissue repair products for the ~~six~~nine months ended ~~June~~September 30, 2017 increased 7% on a reported basis (8% on a constant currency basis) compared to the prior year period. Net sales in this product line were favorably impacted by growth in sales of synthetic hernia repair products and hernia fixation products and were partially offset by declines in sales of natural tissue hernia repair products, a trend that may continue.

Consolidated net sales of Ports for the quarter ended June 30, 2017 increased 7% on a reported basis (8% on a constant currency basis) compared to the prior year quarter. Consolidated net sales of Ports for the six months ended June 30, 2017 increased 5% on a reported basis (6% on a constant currency basis) compared to the prior year period.

Consolidated net sales of ~~dialysis~~biosurgery ~~access~~products ~~catheters~~ for the quarter ~~and six months~~ ended ~~June~~ September 30, 2017 decreased ~~increased 7~~13% on both a reported basis and constant currency basis compared to the prior year ~~periods~~quarter. Consolidated net sales of ~~vascular~~biosurgery ~~access~~products ~~ultrasound devices~~ for the ~~quarter~~nine months ended ~~June~~September 30, 2017 ~~increased~~decreased 1% on both a reported basis ~~(2%~~and ~~on a~~ constant currency basis) compared to the prior year ~~quarter~~period. ~~Consolidated~~The decline in net sales ofin ~~vascular~~this ~~access~~product ~~ultrasound~~line ~~devices~~was ~~for~~primarily ~~the~~due ~~six~~to ~~months~~a ~~ended~~decline ~~June 30,~~in ~~2017~~sales ~~decreased~~of 2%surgical onsealants ~~both~~due to a ~~reported~~supply ~~basis~~issue ~~and~~with ~~constant~~the ~~currency~~company’s ~~basis compared~~surgical sealant line that is expected to be resolved in the ~~prior~~first ~~year~~half ~~period~~of 2018, and was partially offset by growth in sales of hemostats.

Surgical Specialty Products - Surgical specialty products include soft tissue repair products, performance irrigation devices and biosurgery products, including hemostats and sealants. Consolidated net sales of surgical specialty products for the quarter ended June 30, 2017 increased 6% on a reported basis (7% on a constant currency basis) compared to the prior year quarter. Consolidated net sales of surgical specialty products for the six months ended June 30, 2017 increased 8% on both a reported basis and constant currency basis compared to the prior year period. These increases were primarily due to growth in sales of synthetic hernia repair products and were partially offset by declines in sales of natural hernia repair products. United States net sales of surgical specialty products for the quarter ended June 30, 2017 increased 4% compared to the prior year quarter. International net sales of surgical specialty products for the quarter ended June 30, 2017 increased 13% on a reported basis (17% on a constant currency basis) compared to the prior year quarter. United States net sales of surgical specialty products for the six months ended June 30, 2017 increased 5% compared to the prior year period. International net sales of surgical specialty products for the six months ended June 30, 2017 increased 17% on a reported basis (21% on a constant currency basis) compared to the prior year period.

The soft tissue repair product line includes synthetic and natural tissue hernia repair implants, natural tissue breast reconstruction implants and hernia fixation products. Consolidated net sales of soft tissue repair products for the quarter ended June 30, 2017 increased 8% on a reported basis (9% on a constant currency basis) compared to the prior year quarter. Consolidated net sales of soft tissue repair products for the six months ended June 30, 2017 increased 10% on both a reported basis and constant currency basis compared to the prior year period. Net sales in this product line were favorably impacted by growth in sales of synthetic hernia repair products and hernia fixation products and were partially offset by declines in sales of natural tissue hernia repair products, a trend that may continue.

Consolidated net sales of biosurgery products for the quarter ended June 30, 2017 increased 7% on both a reported basis and constant currency basis compared to the prior year quarter. Consolidated net sales of biosurgery products for the six months ended June 30, 2017 increased 5% on both a reported basis and constant currency basis compared to the prior year period. Net sales in the product line were favorably impacted by growth in sales of hemostats. This increase was partially offset by a decline in surgical sealants due to a supply issue that is expected to be resolved in 2017.

Other Products - The other product group includes irrigation, wound drainage and certain original equipment manufacturers’ products.

Costs and Expenses

A summary of costs and expenses as a percentage of net sales is as follows:

	Quarter EndedJune 30,						Six Months EndedJune 30,
	Quarter EndedSeptember 30,						Nine Months EndedSeptember 30,
	2017(A)			2016			2017			2016
	2017			2016			2017			2016(A)
Cost of goods sold		3638.93	%		37.74	%		37.36	%		37.23	%
Marketing, selling and administrative expense		2928.34	%		2928.9	%		29.94	%		3029.49	%
Research and development expense		7.62	%		7.79	%		7.54	%		7.78	%
Interest expense		1.5	%		1.46	%		1.6	%		1.4	%
Other (income) expense, net		712.49	%		112.03	%		47.43	%		36.97	%
Total costs and expenses		8288.83	%		7788.71	%		8083.73	%		8083.62	%

^(A)	Amounts do not add due to rounding.

Cost of goods sold - Cost of goods sold consists principally of the manufacturing and distribution costs of the company’s products. The category also includes royalties paid by the company, amortization of intangible assets and the impact of certain hedging activities. Cost of goods sold as a percentage of net sales for the quarter and nine months ended September 30, 2017 increased 90 basis points and 30 basis points, respectively, compared to the prior year periods primarily due to hurricane-related charges of $11.4 million, consisting of inventory and fixed asset write-offs, charges related to the recovery efforts and manufacturing variances in Puerto Rico, and was partially offset by exchange rate fluctuations. The prior year nine month period included the net effect of the recognition of previously deferred profit on product shipments to the Medicon joint venture prior to its acquisition, the reversal of liabilities with respect to certain revenue-based and manufacturing-related milestones, and an asset impairment.

Marketing, selling and administrative expense - Marketing, selling and administrative expense consists principally of the costs associated with the company’s sales and administrative organizations. These costs as a percentage of net sales for both the quarter and nine months ended September 30, 2017 decreased 50 basis points compared to the prior year periods. The amounts for the nine months ended September 30, 2017 reflect the reversal of accruals for certain product liability matters.

Research and development expense - Research and development expense consists principally of costs related to internal research and development activities, third-party research and development activities, and acquired in-process R&D (“IPR&D”) arising from the company’s business development activities. IPR&D costs may impact the comparability of the company’s results of operations between periods. Research and development expense for the quarter ended September 30, 2017 was $71.7 million, a decrease of approximately 3% compared to the prior year quarter. Research and development expense for the nine months ended September 30, 2017 was $216.2 million, an increase of approximately 1% compared to the prior year period. The amount for the nine months ended September 30, 2017 included a charge of $1.5 million related to the acquisition of early-stage technology.

Interest expense - Interest expense was $14.9 million for both the quarters ended September 30, 2017 and 2016. Interest expense was $45.1 million and $39.6 million for the nine months ended September 30, 2017 and 2016, respectively. The increase in interest expense for the nine months ended September 30, 2017 is primarily due to the May 2016 issuance of fixed-rate notes and the impact from the amortization of the related forward-starting interest rate swap.

Cost of goods sold - Cost of goods sold consists principally of the manufacturing and distribution costs of the company’s products. The category also includes royalties paid by the company, amortization of intangible assets and the impact of certain hedging activities. Cost of goods sold as a percentage of net sales for the quarter ended June 30, 2017 decreased 80 basis points compared to the prior year quarter primarily due to exchange rate fluctuations. Cost of goods sold for the six months ended June 30, 2017 increased 10 basis points compared to the prior year period. The prior year quarter and six month periods included the net effect of the recognition of previously deferred profit on product shipments to the Medicon joint venture prior to its acquisition and an asset impairment. The prior year six month period also included the reversal of liabilities with respect to certain revenue-based and manufacturing-related milestones, which was partially offset by exchange rate fluctuations.

Marketing, selling and administrative expense - Marketing, selling and administrative expense consists principally of the costs associated with the company’s sales and administrative organizations. These costs as a percentage of net sales for the quarter and six months ended June 30, 2017 decreased 60 basis points and 50 basis points, respectively, compared to the prior year periods. The amounts for both the quarter and six months ended June 30, 2017 also reflect the reversal of accruals for certain product liability matters.

Research and development expense - Research and development expense consists principally of costs related to internal research and development activities, third-party research and development activities, and acquired in-process R&D (“IPR&D”) arising from the company’s business development activities. IPR&D costs may impact the comparability of the company’s results of operations between periods. Research and development expense for the quarter ended June 30, 2017 was $74.5 million, an increase of approximately 4% compared to the prior year quarter. Research and development expense for the six months ended June 30, 2017 was $144.5 million, an increase of approximately 4% compared to the prior year period. The amounts for both the quarter and six months ended June 30, 2017 included a charge of $1.5 million related to the acquisition of early-stage technology.

Interest expense - Interest expense was $15.1 million and $13.4 million for the quarters ended June 30, 2017 and 2016, respectively. Interest expense was $30.2 million and $24.7 million for the six months ended June 30, 2017 and 2016, respectively. The increase in interest expense for the quarter and six months ended June 30, 2017 is primarily due to the May 2016 issuance of fixed-rate notes and the impact from the amortization of the related forward-starting interest rate swap.

Other (income) expense, net - The components of other (income) expense, net, are as follows:

	Quarter EndedJune 30,						Six Months EndedJune 30,
	Quarter EndedSeptember 30,						Nine Months EndedSeptember 30,
	2017			2016			2017			2016
(dollars in millions)
Interest income	$	(12.1	)	$	(0.4	)	$	(13.89	)	$	(01.71	)
Foreign exchange losses (gains)		1.67			~~(2.~~0.9	)		—1.7			(3.90	)
Litigation charges		66115.17			—110.6			78194.30			48159.95
BD transaction costs		611.64			—			618.60			—
Restructuring and productivity initiative costs		20.54			114.96			5.26			2126.73
Gore Proceeds		~~(2.4~~—	)		—			(2.4	)		—
Acquisition-related items		0.1			0.2			0.34			34.91
Other, net		(0.72	)		(0.1	)		(0.97	)		(0.34	)
Total other (income) expense, net	$	72127.74		$	9115.68		$	85212.37		$	69185.64

Litigation charges – For the quarter and ~~six~~nine months ended ~~June~~September 30, 2017, the amounts reflect the ~~estimated~~ estimated costs for product liability matters and litigation-related defense costs of $1411.16 million and $1830.84 million, respectively, in connection with the United States District Court for the Southern District of West Virginia’s pre-trial order to prepare additional individual cases for trial. The ~~six~~nine months ended ~~June~~September 30, 2017 also reflects a charge of $7.5 million for Civil Investigative Demands received from a number of State Attorneys General. For the ~~six~~quarter and nine months ended ~~June~~September 30, 2016, the amount reflects the estimated costs for product liability matters. See Note 8 of the notes to condensed consolidated financial statements.

BD transaction costs – For the quarter and ~~six~~nine months ended ~~June~~September 30, 2017, the amounts reflect transaction costs and integration costs incurred in connection with the company’s proposed merger with BD.

25Restructuring and productivity initiative costs – For the quarter and nine months ended September 30, 2017 and 2016, the amounts primarily reflect costs incurred in connection with productivity initiatives to optimize and streamline certain manufacturing and administrative functions to better align resources to the company’s business strategies. Key activities under these initiatives may include systems enhancements, the implementation of shared services centers designed to standardize and centralize processes or the outsourcing of certain services. Productivity initiative costs include consulting costs, primarily related to program creation and management, employee separation costs under the company’s existing severance program, and other related costs.

~~Table~~Gore Proceeds – For the nine months ended September 30, 2017, the amounts reflect the settlement of ~~Contents~~the remaining lawsuits with Gore. See Note 8 of the notes to condensed consolidated financial statements.

~~Restructuring~~Acquisition-related ~~and~~items ~~productivity initiative costs~~ – For the quarter and ~~six~~nine months ended ~~June~~ September 30, ~~2017~~ ~~and 2016~~2017, the ~~amounts~~amount primarily ~~reflect~~consists ~~costs~~of ~~incurred~~purchase inaccounting ~~connection with productivity initiatives to optimize and streamline certain manufacturing and administrative functions to better align resources to the company’s business strategies~~adjustments. ~~Key~~For ~~activities under these initiatives may include systems enhancements,~~ the ~~implementation~~quarter ~~of shared services centers designed to standardize~~ and ~~centralize~~nine ~~processes~~months orended ~~the outsourcing of certain services. Productivity initiative costs include consulting costs~~September 30, ~~primarily related to program creation and management~~2016, ~~employee separation costs under~~ the ~~company’s~~amount ~~existing~~primarily ~~severance~~consists ~~program,~~of ~~and other~~ acquisition-related integration costs.

Gore Proceeds – For the quarter and six months ended June 30, 2017, the amounts reflect the settlement of the remaining lawsuits with Gore. See Note 8 of the notes to condensed consolidated financial statements.

Acquisition-related items – For the quarter and six months ended June 30, 2017, the amount primarily consists of purchase accounting adjustments. For the quarter and six months ended June 30, 2016, the amount primarily consists of acquisition-related integration costs.

Income Tax Provision

The effective tax rate for the quarter and ~~six~~nine months ended ~~June~~September 30, 2017 was 1718.25% and 1415.2%, respectively. As discussed in Note 1 of the notes to condensed consolidated financial statements, the company adopted an accounting standard update that resulted in in the recognition of excess tax benefits to the income tax provision upon settlement of share-based compensation awards. As a result, the effective tax rate for the quarter and ~~six~~nine months ended ~~June~~September 30, 2017 reflected a benefit of $1012.~~5 million~~8 million and $3750.53 million, respectively. In addition, the effective tax rate for the quarter and ~~six~~nine months ended ~~June~~September 30, 2017 reflected the discrete tax effects of litigation charges. See Note 8 of the notes to condensed consolidated ~~financial~~ financial statements.

Net Income and Earnings Per Share Available to Common Shareholders

The company reported net income and diluted earnings per share available to common shareholders for the quarter ended ~~June~~September 30, 2017 of of $~~139~~94.71 million and $1.8625, respectively. Net income and diluted earnings per share available to common shareholders for the prior year quarter were $~~159~~96.24 million and $21.1127, respectively. The current year quarter reflects ~~litigation charges of~~ $50.3 million, or $0.67 per diluted share, amortization of intangible assets of $21.2 million, or $0.28 per diluted share, BD transaction costs of $6.1 million, or $0.08 per diluted share, charges from acquisition-related items (primarily consisting of an IPR&D charge and integration costs) of $1.9 million, or $0.03 per diluted share, restructuring and productivity initiative costs of $1.7 million, or $0.02 per diluted share, and Gore Proceeds of $1.5 million, or $0.02 per diluted share. The prior year quarter reflects amortization of intangible assets of $21.7 million, or $0.29 per diluted share, restructuring and productivity initiative costs of $7.8 million, or $0.10 per diluted share, net charges from acquisition-related items (primarily consisting of integration costs and purchase accounting adjustments) of $2.3 million, or $0.03 per diluted share, and an asset impairment of $1.2 million, or $0.02 per diluted share.

~~The~~25 company reported net income and diluted earnings per share available to common shareholders for the six months ended June 30, 2017 of $317.8 million and $4.23, respectively. Net income and diluted earnings per share available to common shareholders for the prior year period were $275.4 million and $3.64, respectively. The current year six month period reflects litigation charges of $62.4 million, or $0.83 per diluted share, amortization of intangible assets of $42.4 million, or $0.57 per diluted share, BD transaction costs of $6.1 million, or $0.08 per diluted share, charges from acquisition-related items (primarily consisting of integration costs, transaction costs and an IPR&D charge) of $4.5 million, or $0.06 per diluted share, restructuring and productivity initiative costs of $3.1 million, or $0.04 per diluted share, and Gore Proceeds of $1.5 million, or $0.02 per diluted share. The prior year six month period reflects amortization of intangible assets of $43.1 million, or $0.57 per diluted share, litigation charges of $30.8 million, or $0.41 per diluted share, restructuring and productivity initiative costs of $14.4 million, or $0.19 per diluted share, net charges from acquisition-related items (primarily consisting of integration costs, purchase accounting adjustments and transaction costs) of $4.3 million, or $0.06 per diluted share, and an asset impairment of $1.2 million, or $0.02 per diluted share.

litigation charges of $91.6 million, or $1.21 per diluted share, amortization of intangible assets of $21.5 million, or $0.28 per diluted share, hurricane-related charges of $11.1 million, or $0.15 per diluted share, BD transaction costs of $9.3 million, or $0.12 per diluted share, net charges from acquisition-related items (primarily consisting of integration costs, transaction costs and purchase accounting adjustments) of $0.5 million, or $0.01 per diluted share, and a net benefit from restructuring and productivity initiative costs of $0.2 million, which had a nominal impact to diluted earnings per share. The prior year quarter reflects litigation charges of $77.5 million, or $1.02 per diluted share, amortization of intangible assets of $21.6 million, or $0.29 per diluted share, charges from acquisition-related items (primarily consisting of integration costs) of $3.5 million, or $0.05 per diluted share, and restructuring and productivity initiative costs of $3.1 million, or $0.04 per diluted share. The prior year quarter also reflects a $2.6 million, or $0.03 per diluted share, benefit to the income tax provision as a result of the completion of certain IRS examinations.

The company reported net income and diluted earnings per share available to common shareholders for the nine months ended September 30, 2017 of $411.9 million and $5.47, respectively. Net income and diluted earnings per share available to common shareholders for the prior year period were $371.8 million and $4.92, respectively. The current year nine month period reflects litigation charges of $154.0 million, or $2.05 per diluted share, amortization of intangible assets of $63.9 million, or $0.85 per diluted share, BD transaction costs of $15.4 million, or $0.21 per diluted share, hurricane-related charges of $11.1 million, or $0.15 per diluted share, net charges from acquisition-related items (primarily consisting of integration costs, transaction costs and an IPR&D charge) of $5.0 million, or $0.07 per diluted share, net charges from restructuring and productivity initiative costs of $2.9 million, or $0.04 per diluted share, and Gore Proceeds of $1.5 million, or $0.02 per diluted share. The prior year nine month period reflects litigation charges of $108.3 million, or $1.43 per diluted share, amortization of intangible assets of $64.7 million, or $0.86 per diluted share, restructuring and productivity initiative costs of $17.5 million, or $0.23 per diluted share, net charges from acquisition-related items (primarily consisting of integration costs, purchase accounting adjustments and transaction costs) of $7.8 million, or $0.10 per diluted share, and an asset impairment of $1.2 million, or $0.02 per diluted share. The prior year nine month period also reflects a $2.6 million, or $0.03 per diluted share, benefit to the income tax provision as a result of the completion of certain IRS examinations.

Liquidity and Capital Resources

The company assesses its liquidity in terms of its ability to generate cash to fund its operating, investing and financing activities. Significant factors affecting the management of liquidity are cash flows generated from operating activities, capital expenditures, acquisitions of businesses and technologies, cash dividends and common stock repurchases. Cash provided from operations continues to be a primary source of funds. The company believes that it could borrow adequate funds at competitive terms should it be necessary. The company also believes that its overall financial strength gives it sufficient financial flexibility. A summary of certain liquidity measures for the company as of ~~June~~September 30, is as follows:

	2017		2016
(dollars in millions)
Working capital	$	~~877~~1,086.51	$	1,~~145~~312.30
Current ratio		1.5872/1		2.2450/1

Cash and cash equivalents held by the company’s foreign subsidiaries were $~~974~~1,033.01 million and $806.0 million at ~~June~~September 30, 2017 and December 31, 2016, respectively. It is the company’s intention to permanently reinvest the majority of these funds outside the United States to finance foreign operations, and the company’s plans do do not demonstrate a need to repatriate these funds. If these funds are needed for U.S. operations for currently unforeseen circumstances or can no longer be permanently reinvested outside the United States, the company would be required to accrue ~~and~~ and pay U.S. taxes on the earnings associated with these funds. In the United States, ongoing operating cash flows and available borrowings under the company’s committed syndicated bank credit facility provide it with sufficient liquidity.

For the ~~six~~nine months ended ~~June~~September 30, 2017 and 2016, net cash provided by operating activities was $~~317~~526.08 million and $~~156~~344.1 2 million, respectively. The increase in net cash provided by operating activities is primarily due to higher payments to claimants for certain product liability matters in the prior year period, a settlement payment pursuant to an agreement with Medtronic plc in the prior year period (see Note 8 of the notes to condensed consolidated financial statements), ~~higher payments to claimants for certain product liability matters in the prior year period,~~ a payment related to the settlement of the forward starting interest rate swap contact in the prior year period, and lower tax payments in the current year period.

For the ~~six~~nine months ended ~~June~~September 30, 2017 and 2016, net cash used by investing activities was $6599.0 million and $~~241~~268.6 0 million, respectively. Capital expenditures were approximately $4770.37 million and $3864.46 million for the ~~six~~nine months ended ~~June~~September 30, 2017 and 2016, respectively. The company spent $1720.7 3 million and $203.24 million for the acquisition of businesses, products and technology to augment existing product lines for the ~~six~~nine months ended ~~June~~September 30, 2017 and 2016, respectively.

~~For~~26 the six months ended June 30, 2017, net cash used for financing activities was $240.2 million compared to the $62.4 million provided by financing activities for the six months ended June 30, 2016. Total debt was $1.7 billion (including current maturities of $513.6 million) and $1.6 billion at June 30, 2017 and December 31, 2016, respectively. Total debt to total capitalization was 47.2% and 49.5% at June 30, 2017 and December 31, 2016, respectively. The six months ended June 30, 2016 reflects the redemption of $250 million of fixed-rate debt. Net cash used in financing activities also reflects $232.3 million used to repurchase 1,000,000 shares of common stock in the six months ended June 30, 2017 compared to $190.0 million to repurchase 1,000,004 shares of common stock in the prior year period. The company paid cash dividends of $0.52 per share and $0.48 per share for the six months ended June 30, 2017 and 2016, respectively.

The company maintains a $1.0 billion five-year committed syndicated bank credit facility that expires in November 2021. The credit facility supports the company’s commercial paper program and can be used for general corporate purposes. The facility includes pricing based on the company’s long-term credit ratings and includes a financial covenant that limits the amount of total debt to total capitalization. At June 30, 2017, the company was in compliance with this covenant. The company had commercial paper borrowings outstanding of $14.0 million at June 30, 2017. There were no commercial paper borrowings outstanding at December 31, 2016.

For the nine months ended September 30, 2017, net cash used for financing activities was $256.3 million compared to the $41.9 million provided by financing activities for the nine months ended September 30, 2016. Total debt was $1.6 billion (including current maturities of $499.8 million) and $1.6 billion at September 30, 2017 and December 31, 2016, respectively. Total debt to total capitalization was 44.9% and 49.5% at September 30, 2017 and December 31, 2016, respectively. The nine months ended September 30, 2016 reflects the redemption of $250 million of fixed-rate debt and net proceeds of $495.6 million from the issuance of the 3.000% fixed-rate notes due 2026. Net cash used in financing activities also reflects $232.3 million used to repurchase 1,000,000 shares of common stock in the nine months ended September 30, 2017 compared to $231.8 million to repurchase 1,190,004 shares of common stock in the prior year period. The company paid cash dividends of $0.78 per share and $0.74 per share for the nine months ended September 30, 2017 and 2016, respectively.

The company maintains a $1.0 billion five-year committed syndicated bank credit facility that expires in November 2021. The credit facility supports the company’s commercial paper program and can be used for general corporate purposes. The facility includes pricing based on the company’s long-term credit ratings and includes a financial covenant that limits the amount of total debt to total capitalization. At September 30, 2017, the company was in compliance with this covenant. There were no commercial paper borrowings outstanding at September 30, 2017 or December 31, 2016.

Contingencies

In the ordinary course of business, the company is subject to various legal proceedings and claims, including product liability matters, environmental matters, employment disputes, contractual disputes on agreements and other commercial disputes. In addition, the company operates in an industry susceptible to significant patent legal claims. At any given time in the ordinary course of business, the company is involved as either a plaintiff or defendant in a number of patent infringement actions. See Note 8 of the notes to condensed consolidated financial statements.

Certain Regulatory Matters

In the second quarter of 2016, the United States Food and Drug Administration (“FDA”) conducted an inspection at another of the company’s facilities after which the FDA issued a Form-483 to the company in connection with this inspection. The company responded to the FDA, ~~is in the process of addressing the observations in the Form-483,~~ and ~~intends~~took ~~to fully implement~~ corrective and preventive actions to address the FDA’s concerns. However, the company cannot give any assurances that the FDA will be satisfied with its response to the Form-483 or to the expected date of resolution of matters included in the Form-483. Although the company cannot give any assurances that the resolution of this matter will not have a material adverse effect on the company’s business, results of operations, financial conditions and/or liquidity, the company does not at this time believe this will have a material impact on its financial statements.

Management’s Use of Non-GAAP Measures

Net sales “on a constant currency basis” is a non-GAAP measure. The company analyzes net sales on a constant currency basis to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on net sales, the company believes that evaluating growth in net sales on a constant currency basis provides an additional and meaningful assessment of net sales to both management and the company’s investors. Constant currency growth rates are calculated by translating the prior year’s local currency sales by the current period’s exchange rate. Constant currency growth rates are not indicative of changes in corresponding cash flows. The limitation of these non-GAAP measures is that they do not reflect results on a standardized reporting basis. Non-GAAP measures are intended to supplement the applicable GAAP disclosures and should not be viewed as replacements of GAAP results.

Critical Accounting Policies

The preparation of financial statements requires the company’s management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical accounting policies are those that require application of management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Such policies are summarized in the Management’s Discussion and Analysis of Financial Condition and Results of Operations section in Bard’s 2016 Annual Report on Form 10-K. There have been no significant changes to the company’s critical accounting policies since December 31, 2016.

Risks and Uncertainties; Cautionary Statement Regarding Forward-Looking Information

Certain statements contained herein or in other company documents and certain statements that may be made by management of the company orally may contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “forecast,” “plan,” “believe” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to product approvals, future performance of current and anticipated products, sales efforts, expenses, the outcome of contingencies, such as legal proceedings, and financial results. The company’s forward-looking statements speak only as of the date of this report or as of the date they are made, and the company undertakes no obligation to update its forward-looking statements.

2827

expenses, the outcome of contingencies, such as legal proceedings, and financial results. The company’s forward-looking statements speak only as of the date of this report or as of the date they are made, and the company undertakes no obligation to update its forward-looking statements.

In addition, there are substantial risks inherent in the medical device business. The company’s business involves the design, development, manufacture, packaging, distribution and sale of life-sustaining medical devices. These devices are often used on, or permanently or temporarily implanted in, patients in clinically demanding circumstances, such as operating rooms, emergency units, intensive care and critical care settings, among others. These circumstances, among other factors, can cause the products to become associated with adverse clinical events, including patient mortality and injury, and could lead to product liability claims (including lawsuits seeking class action status or seeking to establish multi-district litigation proceedings) and other litigation, product withdrawals, warning letters, recalls, field corrections or regulatory investigations or enforcement actions relating to one or more of the company’s products, any of which could have a material adverse effect on our business, results of operations, financial condition and/or liquidity. For further discussion of risks applicable to our business, see “Risk Factors” in Bard’s 2016 Annual Report on Form 10-K and Bard’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2017.

Because actual results are affected by these and other risks and uncertainties, the company cautions investors that actual results may differ materially from those expressed or implied. It is not possible to predict or identify all risks and uncertainties, but the most significant factors, in addition to those addressed above and those described under Item 1A. “Risk Factors” in Bard’s 2016 Annual Report on Form 10-K and Item 1A. “Risk Factors” in Bard’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, that could adversely affect our business or cause the actual results to differ materially from those expressed or implied include, but are not limited to:

Effective management of and reaction to risks involved in our business, including:

•

the ability to achieve manufacturing or administrative efficiencies, including gross margin benefits from our manufacturing processes and supply chain programs or in connection with the integration of acquired businesses;

•

the effects of negative publicity and/or adverse media coverage concerning our products, competitors’ products, the geographic or product markets in which we compete or our industry in general, which could result in product withdrawals, decreased product demand or adverse reputational effects and which could reduce market or governmental acceptance of our products;

•

the ability to identify appropriate companies, businesses and technologies as potential acquisition candidates, to consummate and successfully integrate such transactions or to obtain agreements for such transactions on favorable terms;

•

the reduction in the number of procedures using our devices caused by customers’ cost-containment pressures or preferences for alternate therapies;

•

the ability to implement, and realize the benefits of, our prior and planned investments in our business, including research and development expenditures focused on new market categories, and our plan to grow in emerging and/or faster-growing markets outside the United States and acquire growth platforms designed to change the mix of our portfolio towards faster, sustainable long-term growth;

•

the uncertainty of whether research and development expenditures and sales force expansion will result in increased sales;

•

the ability to reduce exposure and uncertainty related to tax audits, appeals and litigation;

•

the risk that the company may not successfully implement its expansion of its Enterprise Resource Planning (“ERP”) information system and other productivity initiatives, including ongoing efforts to outsource certain information technology system functions and services;

•

internal factors, such as retention of key employees, including sales force employees;

•

the ability to achieve earnings forecasts, which are generated based, among other things, on projected volumes and sales of many product types, some of which are more profitable than others, and projected royalty revenue from Gore;

•

changes in factors and assumptions or actual results that differ from our assumptions on stock valuation and employee stock option exercise patterns, which could cause compensation and tax expense recorded in future periods to differ significantly from the compensation expense recorded in the current period;

•

changes in factors and assumptions could cause pension cost recorded in future periods to differ from the pension cost recorded in the current period;

2928

•

the effect of market fluctuations on the value of assets in the company’s pension plans and the possibility that the company may need to make additional contributions to the plans as a result of any decline in the fair value of such assets;

• damage to a facility where our products are manufactured or from which they are distributed, which could render the company unable to manufacture or distribute one or more products and may require the company to reduce the output of products at the damaged facility thereby making it difficult to meet product shipping targets, such as occurred in the company’s manufacturing facility in Puerto Rico;

•

the potential impairment of goodwill and intangible assets of the company resulting from insufficient cash flow generated from such assets specifically, or our business more broadly, so as to not allow the company to justify the carrying value of the assets;

•

the ability to obtain appropriate levels of insurance on reasonable terms, or at all;

•

the ability to recover for claims made to our insurance companies or under indemnification obligations to the company and that any amounts recovered under these arrangements may not be adequate to cover the company’s damages and/or costs; and

•

the ability to realize the anticipated benefits of our restructuring activities and productivity initiatives to improve the company’s overall cost structure and improve efficiency.

Competitive factors, including:

•

the trend of consolidation in the medical device industry as well as among our customers, resulting in potentially greater pricing pressures, competition and more significant and complex contracts than in the past, both in the United States and abroad;

•

development of new products or technologies by competitors having superior performance or economic benefit compared to our current products or products under development which could negatively impact sales of our products or render one or more of our products obsolete;

•

technological advances, patents and registrations obtained by competitors that would have the effect of excluding the company from new market segments or preventing the company from selling a product or including key features in the company’s products;

•

attempts by competitors to gain market share through aggressive marketing programs; and

•

reprocessing by third-party reprocessors of our products designed and labeled for single use.

Difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, including:

•

the ability to complete planned and/or ongoing clinical trials successfully, to develop and obtain regulatory approval for products on a timely basis and to launch products on a timely basis within cost estimates;

•

lengthy and costly regulatory approval processes, which may result in lost market opportunities and/or delayed product launches;

•

delays or denials of, or grants of low or reduced levels of reimbursement for, procedures using newly developed products;

•

the suspension or revocation of authority to manufacture, market or distribute existing products;

•

the imposition of additional or different regulatory requirements, such as those affecting manufacturing and labeling;

•

performance, efficacy, quality or safety concerns for existing products, whether scientifically justified or not, that may lead to product discontinuations, product withdrawals, recalls, field corrections, regulatory investigations or enforcement actions, litigation or declining sales, including adverse events and/or concerns relating to the company’s vena cava filters, pelvic floor repair products and hernia repair products;

•

FDA inspections resulting in Form-483 notices and/or warning letters identifying deficiencies in the company’s manufacturing practices and/or quality systems; warning letters identifying violations of FDA regulations that could result in product holds, recalls, restrictions on future clearances by the FDA and/or civil penalties; uncertainty regarding the expected date of resolution of any of these matters;

•

the failure to obtain, limitations on the use of, or the loss of, patent and other intellectual property rights, and the failure of efforts to protect our intellectual property rights against infringement and legal challenges that can increase our costs;

•

difficulties obtaining necessary components or raw materials used in the company’s products and/or price increases from the company’s suppliers of critical components or raw materials, including oil-based resins, or other interruptions of the supply chain; and

•

customers that may limit the number of manufacturers or vendors from which they will purchase products, which can result in the company’s inability to sell products to or contract with large hospital systems, integrated delivery networks or group purchasing organizations.

Governmental action, including:

•

the impact of continued healthcare cost containment;

•

new laws and judicial decisions related to healthcare availability, healthcare reform, payment for healthcare products and services or the marketing and distribution of products, including legislative or administrative reforms to the United States Medicare and Medicaid systems or other United States or international reimbursement systems in a manner that would significantly reduce or eliminate reimbursements for procedures that use the company’s products;

•

changes in the FDA and/or foreign regulatory approval processes that may delay or prevent the approval of new products and result in lost market opportunity;

•

the impact of compliance, investigation and enforcement activities affecting the healthcare industry in general or the company in particular (including sales and marketing practices);

•

changes in tax laws and long-standing tax principles affecting our business, such as the potential for comprehensive tax reform in the United States, the potential for the imposition of taxes, or increased tariffs, on goods produced outside of the United States and imported to the United States, and the impact within multiple jurisdictions resulting from the adoption of Organisation for Economic Co-operation and Development (OECD) policies through its base erosion and profit shifting project;

•

changes in environmental laws or standards affecting our business including, among others, compliance with new labeling standards related to ozone-depleting substances;

•

changes in laws that could require facility upgrades or process changes and could affect production rates and output;

•

compliance costs and potential penalties and remediation obligations in connection with environmental laws, including regulations regarding air emissions, waste water discharges and solid waste; and

•

the impact of the final European Union Medical Device Regulation which was published in May 2017, imposing significant additional pre-market and post-market requirements, and may increase the costs for compliance and product development and the ability to release new products in a timely manner.

Legal disputes, including:

•

product liability claims, which may involve lawsuits seeking class action status or seeking to establish multi-district litigation proceedings, including the Hernia Product Claims, the Women’s Health Product Claims and the Filter Product Claims;

•

claims asserting securities law violations;

•

claims asserting, and/or subpoenas seeking information regarding, violations of law, including in connection with federal and/or state healthcare programs (such as Medicare or Medicaid) and/or sales and marketing practices (such as the civil investigative demands received by the company);

•

derivative shareholder actions;

•

claims and subpoenas asserting antitrust violations;

•

environmental claims, including risks relating to accidental contamination or injury from the use of hazardous materials in the company’s manufacturing, sterilization and research activities and the potential for the company to be held liable for any resulting damages; and

•

commercial disputes, including disputes over distribution agreements, license agreements, manufacturing/supply agreements, development/research agreements (including indemnification provisions), acquisition or sale agreements, and insurance policies.

General economic conditions, including:

•

international and domestic business conditions;

•

political or economic instability in foreign countries;

•

interest rates;

•

foreign currency exchange rates;

•

changes in the rate of inflation;

•

instability of global financial markets and economies such as have impacted Greece, Italy, Spain, Portugal, Puerto Rico and certain other countries or places where we operate or do business; and

•

The negotiated terms of the United Kingdom’s departure from the European Union.

The ability of the parties to successfully complete the proposed merger on anticipated terms and timing, including:

• obtaining required ~~shareholder and~~ regulatory approvals;

•

the outcome of any legal proceedings related to the proposed acquisition;

•

successful compliance with governmental regulations applicable to BD, Bard and the combined company; and

•

other factors discussed in BD’s and Bard’s respective filings with the Securities and Exchange Commission.

Other factors beyond our control, including catastrophes, both natural and man-made, earthquakes, floods, fires, explosions, strikes, work stoppages or slowdowns, cyberattacks, acts of terrorism or war.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

The quantitative and qualitative disclosures about market risk are discussed in “Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk” in Bard’s 2016 Annual Report on Form 10-K. There have been no material changes in the information reported since the year ended December 31, 2016.

Item 4. Controls and Procedures

The company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the company’s reports under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosures. Any controls and procedures, no matter how well defined and operated, can provide only reasonable assurance of achieving the desired control objectives.

The company’s management, with the participation of the company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of the company’s disclosure controls and procedures as of ~~June~~September 30, 2017. Based upon that evaluation, the company’s Chief Executive Officer and Chief Financial Officer have concluded that, as of ~~June~~September 30, 2017, the design and operation of the company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were effective to accomplish their objectives at the ~~reasonable~~ reasonable assurance level. There have been no changes in the company’s internal control over financial reporting that occurred during the quarter ended ~~June~~September 30, 2017 that have materially affected, or are reasonably likely to materially affect, the company’s internal control over financial reporting.

3331

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

Product Liability Matters

Hernia Product Claims

As of ~~June~~September 30, 2017, approximately 25 federal and 90185 state lawsuits involving individual claims by approximately ~~115~~ 205 plaintiffs, as well as one putative class action in the United States, are currently pending against the company with respect to its Composix® Kugel® and certain other hernia repair implant products (collectively, the “Hernia Product Claims”). The company voluntarily recalled certain sizes and lots of the Composix® Kugel® products beginning in December 2005. In June 2007, the Composix® Kugel® lawsuits and, subsequently, other hernia repair product lawsuits, pending in federal courts nationwide were transferred into one Multidistrict Litigation (“MDL”) for coordinated pre-trial proceedings in the United States District Court for the District of Rhode Island. The MDL stopped accepting new cases in the second quarter of 2014 and was terminated in November 2016, at which time the remaining federal lawsuits were remanded to their courts of original jurisdiction for trial. As of ~~June~~ September 30, 2017, all but one of the United States putative class actions pending against the company was dismissed. The remaining putative class action pending against the company has not been certified and seeks: (i) medical monitoring; (ii) compensatory damages; (iii) punitive damages; (iv) a judicial finding of defect and causation; and/or (v) attorneys’ fees. In April 2014, a settlement was reached with respect to three putative Canadian class actions within amounts previously recorded by the company. As of ~~June~~September 30, 2017, five new putative Canadian class actions have been filed against the company. Approximately 80170 of the state lawsuits, involving individual claims by approximately 80 170 plaintiffs, are pending in the Superior Court of the State of Rhode Island, with the remainder in various other jurisdictions. The Hernia Product Claims also generally seek damages for personal injury resulting from use of the products.

34Women’s Health Product Claims

lawsuits, unfiled or unknown claims, putative class actions and other claims, together with claims that have settled or are the subject of agreements or agreements in principle to settle, are referred to collectively as the “Women’s Health Product Claims”. The Women’s Health Product Claims generally seek damages for personal injury resulting from use of the products. The putative class actions, none of which has been certified, seek: (i) medical monitoring; (ii) compensatory damages; (iii) punitive damages; (iv) a judicial finding of defect and causation; and/or (v) attorneys’ fees. In April 2015, the Ontario Superior Court of Justice dismissed the plaintiffs’ motion for class certification in one Canadian putative class action. In March 2016, the company reached an agreement in principle to resolve all Canadian putative class actions, with the exception of a Quebec class action, within amounts previously recorded by the company, which settlement was finalized in September 2016. In January 2017, the court approved the discontinuance of the proposed Quebec class action.

AsIn ofOctober ~~June 30~~2010, ~~2017,~~the ~~product~~Women’s ~~liability~~Health ~~lawsuits~~Product Claims involving ~~individual~~solely ~~claims~~Avaulta® products bypending ~~approximately~~in ~~4,170~~federal ~~plaintiffs~~courts ~~are~~nationwide ~~currently~~were ~~pending against~~transferred ~~the~~into ~~company~~an MDL in ~~various~~the ~~federal~~United ~~and~~States ~~state~~District ~~jurisdictions~~Court ~~alleging~~for ~~personal~~the ~~injuries~~Southern ~~associated~~District ~~with~~of West Virginia (the ~~use~~“WV ofDistrict ~~certain~~Court”), the scope of ~~the~~which ~~company~~was later expanded to include lawsuits involving all women’s surgical continence products ~~for~~that ~~women,~~are ~~which~~manufactured ~~includes~~or ~~products~~distributed ~~manufactured~~ by ~~both~~ the company. ~~and two~~The ~~subsidiaries~~first oftrial ~~Medtronic~~in ~~plc~~a ~~(as~~state ~~successor~~court was completed in ~~interest~~California toin ~~Covidien~~July ~~plc)~~2012 ~~(“Medtronic”),~~and ~~each~~resulted in a ~~supplier~~judgment ofagainst the company of approximately $3.6 ~~Medtronic~~million. ~~has~~On anappeal ~~obligation~~the todecision ~~defend~~was ~~and~~affirmed ~~indemnify~~by the appellate court in November 2014. The company ~~with~~filed ~~respect~~a petition for review to ~~any~~the ~~product~~California ~~defect~~Supreme ~~liability~~Court ~~for products~~on ~~its~~December 24, ~~subsidiaries~~2014, ~~had~~which ~~manufactured.~~was Asdenied ~~described~~on ~~below~~February 18, 2015. The judgment in this ~~July~~matter, including interest and costs, was paid on March 20, 2015 within the amounts previously recorded by the company. ~~reached~~The anfirst ~~agreement~~trial ~~with~~in ~~Medtronic~~the (MDL commenced in July 2013 and resulted in a judgment against the company of approximately $2 million, which was ~~amended~~upheld inby ~~June~~the ~~2017)~~Fourth ~~regarding~~Circuit ~~certain~~on ~~aspects~~January 14, 2016. The company does not believe that any verdicts entered to date are representative of ~~Medtronic~~potential outcomes of all Women’s ~~indemnification~~Health ~~obligation~~Product Claims. InOn ~~addition~~January 16, ~~five~~ ~~putative~~2014 ~~class~~and ~~actions~~July 31, in2014, the ~~United~~WV ~~States~~District ~~and~~Court ~~five~~ordered ~~putative~~that ~~class~~the ~~actions~~company inprepare ~~Canada~~200 ~~have~~and ~~been~~then ~~filed~~an ~~against~~additional ~~the~~300 ~~company~~individual cases, ~~and~~respectively, afor ~~limited~~trial ~~number~~(the of“2014 ~~other~~WHP ~~claims~~Pre-Trial ~~have~~Orders”). ~~been~~The ~~filed~~2014 orWHP ~~asserted~~Pre-Trial Orders resulted in significant ~~various~~additional ~~non~~litigation-~~U.S.~~related ~~jurisdictions~~defense costs beginning in the second quarter of 2014 and continuing through the second quarter of 2015. ~~The~~In ~~foregoing~~February ~~lawsuits~~2015, the WV District Court appointed a Special Master to assist with settlement ~~unfiled~~resolution. orIn ~~unknown~~June ~~claims~~2015, ~~putative~~the ~~class~~WV ~~actions~~District ~~and~~Court ~~other~~issued ~~claims,~~an ~~together~~order ~~with~~staying ~~claims~~the ~~that~~requirement ~~have~~to ~~settled~~prepare ora significant portion of the cases covered by the 2014 WHP Pre-Trial Orders. Substantially all of the 500 individual cases that are the subject of the 2014 WHP Pre-Trial Orders have been part of agreements or agreements in principle to settle, ~~are~~with ~~referred~~various toplaintiff ~~collectively~~law asfirms. ~~the~~In ~~“Women’s~~December ~~Health~~2016, ~~Product Claims”.~~the ~~The~~WV ~~Women’s~~District ~~Health~~Court ~~Product~~lifted ~~Claims~~the ~~generally~~stay ~~seek~~of ~~damages~~the ~~for~~2014 ~~personal~~WHP ~~injury~~Pre-Trial ~~resulting~~Orders ~~from~~and ~~use~~remanded five of the ~~products.~~unsettled cases ~~The~~to ~~putative~~their ~~class~~courts ~~actions,~~of ~~none~~original ofjurisdiction ~~which~~for ~~has~~trial. ~~been~~In ~~certified~~the first quarter of 2017, ~~seek:~~an ~~(i) medical~~additional ~~monitoring; (ii) compensatory~~11 ~~damages;~~cases ~~(iii) punitive~~were ~~damages;~~remanded ~~(iv) a~~for ~~judicial~~trial ~~finding~~for a total of ~~defect~~16 ~~and~~remanded ~~causation;~~cases. ~~and/or~~As ~~(v)~~of September ~~attorneys’~~30, ~~fees.~~2017, Inafter ~~April~~accounting ~~2015,~~for settlements effectuated over the ~~Ontario~~second ~~Superior~~and ~~Court~~third quarters of ~~Justice~~2017, ~~dismissed~~there ~~the~~are ~~plaintiffs’~~only ~~motion~~three ~~for class~~remaining ~~certification~~remanded inmatters, ~~one~~of ~~Canadian~~which ~~putative~~two ~~class~~cases ~~action~~have been assigned trial dates in 2018. In response to court orders on January 27, 2017 and March 3, ~~2016~~2017, the company ~~reached~~is preparing an ~~agreement~~additional inapproximately ~~principle~~125 toremaining ~~resolve~~individual ~~all~~cases ~~Canadian~~for ~~putative~~trial ~~class~~(together ~~actions,~~ with the ~~exception~~2014 ofWHP aPre-Trial ~~Quebec~~Orders, ~~class~~the ~~action~~“WHP Pre-Trial Orders”), ~~within~~which ~~amounts~~has ~~previously~~been ~~recorded by~~reduced from the ~~company,~~original ~~which~~order ~~settlement~~due ~~was~~to ~~finalized~~settlements and dismissals over the second and third quarters of 2017. The WHP Pre-Trial Orders may result in ~~September~~material ~~2016~~additional costs in future periods in defending Women’s Health Product Claims. InThe ~~January~~WV ~~2017,~~District ~~the~~Court ~~court~~may ~~approved~~also order that the ~~discontinuance~~company ofprepare ~~the~~additional ~~proposed~~cases ~~Quebec~~for trial, ~~class~~which ~~action~~could result in material additional costs in future periods.

InAs ~~October~~of ~~2010~~September 30, 2017, the ~~Women’s~~company ~~Health~~reached ~~Product Claims involving solely Avaulta®~~agreements ~~products~~or ~~pending~~agreements in ~~federal~~principle ~~courts~~with ~~nationwide~~various ~~were~~plaintiffs’ ~~transferred~~law ~~into~~firms anto ~~MDL~~settle intheir ~~the~~respective ~~United~~inventories ~~States District Court for the Southern District~~ of ~~West~~cases ~~Virginia~~totaling ~~(the~~approximately ~~“WV District Court”)~~13,050 ~~the scope of which was later expanded to include lawsuits involving all women~~Women’s ~~surgical~~Health ~~continence~~Product ~~products~~Claims, ~~that~~including ~~are manufactured or distributed by the company. The first trial in a state court was completed in California in July 2012 and resulted in a judgment against the company of~~ approximately ~~$3.6~~: ~~million.~~560 Onduring ~~appeal the decision was affirmed by the appellate court in November~~ 2014~~. The company filed a petition for review to the California Supreme Court on December 24~~, ~~2014~~6,215 ~~which~~during ~~was denied on February 18,~~ 2015~~. The judgment in this matter~~, ~~including interest and costs~~4,155 during ~~was~~2016 ~~paid on March 20, 2015 within the amounts previously recorded by the company. The first trial in the MDL commenced in July 2013~~ and ~~resulted in a judgment against the company of approximately $~~2 ~~million~~,120 ~~which~~during ~~was upheld by the Fourth Circuit on January 14, 2016~~2017. The company ~~does~~believes ~~not believe~~ that ~~any~~these ~~verdicts entered to date are representative of potential outcomes of all~~ Women’s Health Product Claims. Onare ~~January 16,~~not ~~2014 and July 31, 2014,~~ the WVsubject ~~District~~of ~~Court~~Medtronic’s ~~ordered~~indemnification ~~that~~obligation. ~~the~~These ~~company~~settlement ~~prepare~~agreements ~~200~~ and ~~then~~agreements anin ~~additional~~principle ~~300~~include ~~individual~~unfiled ~~cases,~~and previously ~~respectively,~~unknown ~~for~~claims ~~trial~~held ~~(the~~by ~~“2014~~various ~~WHP~~plaintiffs’ ~~Pre-Trial~~law ~~Orders”).~~firms, ~~The~~which ~~2014~~have ~~WHP~~not ~~Pre-Trial~~been ~~Orders~~included ~~resulted~~ in ~~significant additional litigation-related defense costs beginning in~~ the ~~second~~approximate ~~quarter~~number of ~~2014~~lawsuits ~~and~~set ~~continuing~~forth ~~through~~in the ~~second~~first ~~quarter~~paragraph of ~~2015~~this section. InEach ~~February~~agreement ~~2015,~~is ~~the~~subject ~~WV District Court appointed a Special Master~~ to ~~assist~~certain ~~with~~conditions, ~~settlement resolution. In June~~including ~~2015,~~requirements ~~the~~for WVparticipation ~~District~~in ~~Court issued an order staying~~ the ~~requirement~~proposed tosettlements ~~prepare~~by a ~~significant~~certain ~~portion~~minimum number of ~~the cases covered by the 2014 WHP Pre-Trial Orders~~plaintiffs. ~~Substantially~~The ~~all~~company ofcontinues ~~the~~to ~~500~~engage ~~individual cases that are the subject of the 2014 WHP Pre-Trial Orders have been part of agreements or agreements~~ in ~~principle~~discussions ~~to settle~~ with ~~various~~other ~~plaintiff~~plaintiffs’ law firms. Inregarding ~~December~~potential ~~2016,~~resolution ~~the WV District Court lifted the stay~~ of ~~the 2014 WHP Pre-Trial Orders and remanded five of the~~ unsettled ~~cases to their~~Women’s ~~courts~~Health ofProduct ~~original jurisdiction for trial. In the first quarter of 2017~~Claims, an additional 11 cases were remanded for trial for a total of 16 remanded cases. As of June 30, 2017, after accounting for settlements effectuated over the second quarter of 2017, there are only seven remaining remanded matters, of which ~~four~~may ~~cases~~include ~~have~~additional ~~been~~inventory ~~assigned trial dates between the third quarter of 2017 and the third quarter of 2018~~settlements. InNotwithstanding ~~response~~these tosettlement ~~court orders on January 27~~efforts, ~~2017 and March 3, 2017,~~ the company isanticipates ~~preparing an~~ additional ~~approximately~~trials ~~125 remaining individual cases for trial (together with the 2014 WHP Pre-Trial Orders, the “WHP Pre-Trial Orders”), which has been reduced from the original order due to settlements and dismissals~~ over the ~~second~~next ~~quarter of 2017~~12 months. ~~The~~In ~~WHP~~addition, ~~Pre-Trial~~one ~~Orders~~or ~~may~~more ~~result~~possible inconsolidated ~~material~~trials ~~additional cost in future periods in defending Women’s Health Product Claims. The WV District Court~~ may ~~also order that the company~~ ~~prepare~~occur ~~additional cases for trial, which could result~~ in ~~material~~the ~~additional costs in~~ future ~~periods~~.

~~The~~33 approximate number of lawsuits set forth in the first paragraph of this section does not include approximately 555 generic complaints involving women’s health products where the company cannot, based on the allegations in the complaints, determine whether any of those cases involve the company’s women’s health products. In addition, the approximate number of lawsuits set forth in the first paragraph of this section does not include approximately 825 claims that have been threatened against the company but for which complaints have not yet been filed. In addition, the company has limited information regarding the nature and quantity of these and other unfiled or unknown claims. During the course of engaging in settlement discussions with plaintiffs’ law firms, the company has learned, and may in future periods learn, additional information regarding these and other unfiled or unknown claims, or other lawsuits, which could materially impact the company’s estimate of the number of claims or lawsuits against the company. While the company continues to engage in discussions with other plaintiffs’ law firms regarding potential resolution of unsettled Women’s Health Product Claims and intends to vigorously defend the Women’s Health Product Claims that do not settle, including through litigation, it cannot give any assurances that the resolution of these claims will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

Filter Product Claims

As of ~~June~~September 30, 2017, product liability lawsuits involving individual claims by approximately 2,~~245~~765 plaintiffs are currently pending against the company in various federal and state jurisdictions alleging personal injuries associated with the use of the company’s vena cava filter products (all lawsuits, collectively, the “Filter Product Claims”). In August 2015, the Judicial Panel for Multi-District Litigation (“JPML”) ordered the creation of a Multi-District Litigation for all federal Filter Product Claims (the “IVC Filter MDL”) in the District of Arizona. There are approximately 2,~~175~~ 690 Filter Product Claims that have been, or shortly will be, transferred to the IVC Filter MDL. In September 2017, ~~including~~the ~~one~~Court denied Plaintiffs’ motion seeking class certification of a medical monitoring class. ~~action~~Plaintiffs may appeal this decision. In March 2017, the company filed a motion for summary judgment based upon principles of federal ~~preemption,~~ ~~which is scheduled to be fully briefed by the end of the third quarter of 2017~~preemption. The remaining approximately 6570 Filter Product Claims are pending in various state courts. In March 2016, a putative Canadian class action was filed against the company in Quebec. In April 2016 and May 2016, putative Canadian class actions were filed in Ontario and British Columbia, respectively. In November 2016, a putative Canadian class action was filed in Saskatchewan. The approximate number of lawsuits set forth above does not include approximately 2520 claims that have been threatened against the company but for which complaints have not yet been filed. In addition, the company has limited information regarding the nature and quantity of these and other unfiled or unknown claims. The company continues to receive claims and lawsuits and may in future periods learn additional information regarding other unfiled or unknown claims, or other lawsuits, which could materially impact the company’s estimate of the number of claims or lawsuits against the company. The company expects that trials of Filter Product Claims may take place over the next 12 months. While the company intends to vigorously defend Filter Product Claims that do not settle, including through litigation, it cannot give any assurances that the resolution of these claims will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

General

The company, its directors, BD and Merger Corp were or have been named as defendants in two putative class actions in the United States District Court of the District of New Jersey, under the captions Barbara Stanford Tanguma v. C. R. Bard, Inc., et al., Case No. 2:17-CV-03977 (filed June 2, 2017) (the “Tanguma action”) and Richard K. Maser v. Timothy M. Ring, ~~et al., Case No. 2:17-CV-04549 (filed June 21, 2017) (the “Maser Action” and, together with the Tanguma~~ action, the “lawsuits”). The complaints for the lawsuits allege that the preliminary registration statement on Form S-4 filed by BD on May 23, 2017 contains material misstatements and omits material information in violation of Sections 14(a) and 20(a) of the Exchange Act. The lawsuits seek, among other things, equitable relief to enjoin consummation of the Merger and attorneys’ fees and costs. The Tanguma action also seeks dissemination of a registration statement that is materially true and not misleading and, if the company and BD consummate the Merger, its rescission and/or rescissory damages, and the Maser Action also seeks unspecified damages. The company believes that the lawsuits are without merit.

et al., Case No. 2:17-CV-04549 (filed June 21, 2017) (the “Maser action” and, together with the Tanguma action, the “lawsuits”). The complaint for the Tanguma action alleged, and for the Maser action alleges, that the preliminary registration statement on Form S-4 filed by BD on May 23, 2017 contains material misstatements and omits material information in violation of Sections 14(a) and 20(a) of the Exchange Act. The Tanguma action sought, and the Maser action continues to seek, among other things, equitable relief to enjoin consummation of the Merger and attorneys’ fees and costs. The Tanguma action also sought dissemination of a registration statement that is materially true and not misleading and, if the company and BD consummate the Merger, its rescission and/or rescissory damages, and the Maser action continues to seek unspecified damages. On September 25, 2017, the Tanguma action was voluntarily dismissed by the plaintiffs. The company believes that Maser action is without merit.

Other Legal Matters

In November 2015, the Department of Defense Inspector General issued an investigative subpoena to the company. The Department of Health and Human Services is also participating in this investigation. The subpoena seeks documents related to the company’s sales and marketing of certain filter products, drug coated balloon catheters, and peripheral arterial disease detection products. In July 2017, a separate civil investigative demand was served by the Department of Justice seeking documents and information relating to an investigation into possible violations of the False Claims Act in connection with the sales and marketing of FloChec^® and QuantaFlo^TM devices. The company is cooperating with these requests. Since it is not feasible to predict the outcome of these proceedings, the company cannot give any assurances that the resolution of these proceedings will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

Item 1A. Risk Factors

There have been no material changes to the risk factors disclosed in Part I, Item 1A. in Bard’s 2016 Annual Report on Form 10-K and Part II, Item 1A. in Bard’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2017.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following table provides information with respect to the shares of the company’s common stock repurchased during the quarter ended ~~June~~September 30, 2017:

	Issuer Purchases of Equity Securities
Period	TotalNumberof SharesPurchased(1)		AveragePricePaidPer Share		Total Numberof SharesPurchased asPart of PubliclyAnnouncedPrograms(2)		MaximumApproximateDollar Value ofSharesthat May YetBe PurchasedUnder Plans orPrograms(2)
April 1 – April 30, 2017		652	$	249.37		—	$	257,148,419
July 1 – July 31, 2017		2,724	$	318.05		—	$	257,148,419
May 1 – May 31, 2017		—		—		—		257,148,419
August 1 – August 31, 2017		2,240		321.07		—		257,148,419
June 1 – June 30, 2017		534		315.72		—		257,148,419
September 1 – September 30, 2017		456		320.52		—		257,148,419
Total		15,~~186~~420	$	~~279~~319.2451		—	$	257,148,419

(1) Includes 15,~~186~~420 shares that the company repurchased during the three month period ended ~~June~~September 30, 2017 that were not part of the publicly announced share repurchase authorization. These shares were purchased from employees to satisfy tax withholding requirements on the vesting of restricted shares/units from equity-based awards.

(2)	On June 8, 2016, the company announced that its Board of Directors had authorized the repurchase of up to an additional $500 million of common stock.

Item 5. Other Information

The company’s policy governing transactions in its securities by the company’s directors, executive officers and other specified employees permits such persons to adopt trading plans pursuant to Rule 10b5-1 of the Exchange Act. From time-to-time, the company’s executive officers have established trading plans relating to the company’s common stock under Rule 10b5-1, and the company anticipates additional trading plans may be established in the future. The company currently discloses details regarding individual trading plans on its website.

Item 6. Exhibits

Number		Description
2.1		Agreement and Plan of Merger, dated as of April 23, 2017, by and among C. R. Bard, Inc., Becton, Dickinson and Company and Lamda Corp., filed as Exhibit 2.1 to the company’s April 24, 2017 Form 8-K, is incorporated herein by reference*
4.1		Fourth Supplemental Indenture, dated May 18, 2017, between C. R. Bard, Inc. and Wells Fargo Bank, National Association, as trustee, filed as Exhibit 4.1 to the company’s May 23, 2017 Form 8-K, is incorporated herein by reference
4.2		First Supplemental Indenture, dated May 18, 2017, between C. R. Bard, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee, filed as Exhibit 4.2 to the company’s May 23, 2017 Form 8-K, is incorporated herein by reference
12.1		Computation of Ratio of Earnings to Fixed Charges**
31.1		Rule 13a-14(a) / 15d-14(a) Certification of Chief Executive Officer**
31.2		Rule 13a-14(a) / 15d-14(a) Certification of Chief Financial Officer**
32.1		Section 1350 Certification of Chief Executive Officer (furnished herewith)
32.2		Section 1350 Certification of Chief Financial Officer (furnished herewith)
101.INS		XBRL Instance Document**
101.SCH		XBRL Taxonomy Extension Schema Document**
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document**
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document**
101.LAB		XBRL Taxonomy Extension Label Linkbase Document**
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document**

See Exhibit Index.

*36 Pursuant to Item 601(b)(2) of Regulation S-K, certain schedules and similar attachments have been omitted. The registrant hereby agrees to furnish a copy of any omitted schedule or similar attachment to the SEC upon request.

** Filed herewith.

INDEX TO EXHIBITS


Number		Description

2.1		Amendment No. 1, dated July 28, 2017, to the Agreement and Plan of Merger, dated as of April 23, 2017, among C. R. Bard, Inc., Becton, Dickinson and Company and Lambda Corp., filed as Exhibit 2.1 to the company’s July 28, 2017 Form 8-K, is incorporated herein by reference

10.46*		Amendment to C. R. Bard, Inc. Supplemental Executive Retirement Plan, effective August 2, 2017**

10.47*		Omnibus Amendment to Terms and Conditions of Management Stock Purchase Program Awards (2014 and earlier) under the Company’s 2012 Long Term Incentive Plan (as Amended and Restated), effective August 2, 2017**

10.48*		Omnibus Amendment to Terms and Conditions of Management Stock Purchase Program Awards (2015 and later) under the Company’s 2012 Long Term Incentive Plan (as Amended and Restated), effective August 2, 2017**

10.49*		Omnibus Amendment to Terms and Conditions of Restricted Stock Units Awards under the Company’s 2012 Long Term Incentive Plan (as Amended and Restated), effective August 2, 2017**

10.50*		Omnibus Amendment to Terms and Conditions of Performance Long-Term Incentive Awards under the Company’s 2012 Long Term Incentive Plan (as Amended and Restated), effective August 2, 2017**

10.51*		Omnibus Amendment to the Deferred Compensation Contract, Deferral of Directors’ Fees of C. R. Bard, Inc., effective August 2, 2017**

12.1		Computation of Ratio of Earnings to Fixed Charges**

31.1		Rule 13a-14(a) / 15d-14(a) Certification of Chief Executive Officer**

31.2		Rule 13a-14(a) / 15d-14(a) Certification of Chief Financial Officer**

32.1		Section 1350 Certification of Chief Executive Officer (furnished herewith)

32.2		Section 1350 Certification of Chief Financial Officer (furnished herewith)

101.INS		XBRL Instance Document**

101.SCH		XBRL Taxonomy Extension Schema Document**

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document**

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document**

101.LAB		XBRL Taxonomy Extension Label Linkbase Document**

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document**

*	Each of these exhibits constitutes a management contract or a compensatory plan or arrangement.

**	Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

				C. R. BARD, INC.
				(Registrant)
Date: July 28, 2017
Date: October 26, 2017
				/s/ CHRISTOPHER S. HOLLAND
				Christopher S. Holland Senior Vice President and Chief Financial Officer
				/s/ FRANK LUPISELLA JR.
				Frank Lupisella Jr. Vice President and Controller

4038

INDEX TO EXHIBITS

Number		Description
2.1		Agreement and Plan of Merger, dated as of April 23, 2017, by and among C. R. Bard, Inc., Becton, Dickinson and Company and Lamda Corp., filed as Exhibit 2.1 to the company’s April 24, 2017 Form 8-K, is incorporated herein by reference
4.1		Fourth Supplemental Indenture, dated May 18, 2017, between C. R. Bard, Inc. and Wells Fargo Bank, National Association, as trustee, filed as Exhibit 4.1 to the company’s May 23, 2017 Form 8-K, is incorporated herein by reference
4.2		First Supplemental Indenture, dated May 18, 2017, between C. R. Bard, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee, filed as Exhibit 4.2 to the company’s May 23, 2017 Form 8-K, is incorporated herein by reference
12.1		Computation of Ratio of Earnings to Fixed Charges
31.1		Rule 13a-14(a) / 15d-14(a) Certification of Chief Executive Officer
31.2		Rule 13a-14(a) / 15d-14(a) Certification of Chief Financial Officer
32.1		Section 1350 Certification of Chief Executive Officer (furnished herewith)
32.2		Section 1350 Certification of Chief Financial Officer (furnished herewith)
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

Large accelerated filer

Accelerated filer

Smaller reporting company

Non-accelerated filer

☐ (Do not check if smaller reporting company)

Emerging growth company

Filing Compare · BARD C R INC /NJ/